<SEC-DOCUMENT>0001104659-21-088982.txt : 20210702
<SEC-HEADER>0001104659-21-088982.hdr.sgml : 20210702
<ACCEPTANCE-DATETIME>20210702170532
ACCESSION NUMBER:		0001104659-21-088982
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20210702
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Termination of a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210702
DATE AS OF CHANGE:		20210702

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		211071297

	BUSINESS ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		201-696-9345

	MAIL ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2121219d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:plx="http://protalix.com/20210702">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_plx_protalix.com_20210702 -->
<!-- Field: Set; Name: xdx; ID: xdx_04F_20210702_20210702 -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DEntityCentralIndexKey_0001006281 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-07-02to2021-07-02" name="dei:EntityCentralIndexKey">0001006281</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-07-02to2021-07-02" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="plx-20210702.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-07-02to2021-07-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-02</xbrli:startDate>
        <xbrli:endDate>2021-07-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_907_edei--DocumentType_c20210702__20210702_zo1Us4AO1vD5"><ix:nonNumeric contextRef="From2021-07-02to2021-07-02" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of Earliest Event
Reported): <span id="xdx_900_edei--DocumentPeriodEndDate_c20210702__20210702_zQjZZ0MJMre5"><ix:nonNumeric contextRef="From2021-07-02to2021-07-02" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">July 2, 2021</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_904_edei--EntityRegistrantName_c20210702__20210702_zGkACaBldFW9"><ix:nonNumeric contextRef="From2021-07-02to2021-07-02" name="dei:EntityRegistrantName">Protalix BioTherapeutics, Inc.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of registrant as specified
in its charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr>
    <td style="vertical-align: top; text-align: center; width: 32%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_909_edei--EntityIncorporationStateCountryCode_c20210702__20210702_zxJAWciSC0z2"><ix:nonNumeric contextRef="From2021-07-02to2021-07-02" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: top; text-align: center; width: 32%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_901_edei--EntityFileNumber_c20210702__20210702_z8ehGkNhqPmh"><ix:nonNumeric contextRef="From2021-07-02to2021-07-02" name="dei:EntityFileNumber">001-33357</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: top; text-align: center; width: 32%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_908_edei--EntityTaxIdentificationNumber_c20210702__20210702_z5R3OvmIFYe"><ix:nonNumeric contextRef="From2021-07-02to2021-07-02" name="dei:EntityTaxIdentificationNumber">65-0643773</ix:nonNumeric></span></b></span></td></tr>
<tr>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(State or other jurisdiction</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of incorporation)</b></p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Commission File Number)</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(IRS Employer</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Identification No.)</b></p></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr>
    <td style="vertical-align: top; text-align: center; width: 49%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_905_edei--EntityAddressAddressLine1_c20210702__20210702_zGOHh9iwN8gb"><ix:nonNumeric contextRef="From2021-07-02to2021-07-02" name="dei:EntityAddressAddressLine1">2 University Plaza</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; text-align: center; width: 49%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_908_edei--EntityAddressPostalZipCode_c20210702__20210702_zjly01AVGrHk"><ix:nonNumeric contextRef="From2021-07-02to2021-07-02" name="dei:EntityAddressPostalZipCode">07601</ix:nonNumeric></span></b></span></td></tr>
<tr>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_904_edei--EntityAddressAddressLine2_c20210702__20210702_ze3LzvrmM44b"><ix:nonNumeric contextRef="From2021-07-02to2021-07-02" name="dei:EntityAddressAddressLine2">Suite 100</ix:nonNumeric></span></b></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Zip Code)</b></span></td></tr>
<tr>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_903_edei--EntityAddressCityOrTown_c20210702__20210702_zjlgusPlRwU5"><ix:nonNumeric contextRef="From2021-07-02to2021-07-02" name="dei:EntityAddressCityOrTown">Hackensack</ix:nonNumeric></span></b></span><b>, <span id="xdx_900_edei--EntityAddressStateOrProvince_c20210702__20210702_z0SCcrcOs7B6"><ix:nonNumeric contextRef="From2021-07-02to2021-07-02" name="dei:EntityAddressStateOrProvince">NJ</ix:nonNumeric></span></b></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
<tr>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Address of principal executive offices)</b></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Registrant&#8217;s telephone number, including
area code <span id="xdx_90A_edei--CityAreaCode_c20210702__20210702_z0ZDFzw7QMRf"><ix:nonNumeric contextRef="From2021-07-02to2021-07-02" name="dei:CityAreaCode">201</ix:nonNumeric></span>-<span id="xdx_903_edei--LocalPhoneNumber_c20210702__20210702_zT3uqSVMZ3N9"><ix:nonNumeric contextRef="From2021-07-02to2021-07-02" name="dei:LocalPhoneNumber">696-9345</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Former name or former address, if changed
since last report.)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i>see</i> General Instruction
A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_901_edei--WrittenCommunications_c20210702__20210702_zCWiOHFDiCaf"><ix:nonNumeric contextRef="From2021-07-02to2021-07-02" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Written
communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_905_edei--SolicitingMaterial_c20210702__20210702_zmm1iFigHoMg"><ix:nonNumeric contextRef="From2021-07-02to2021-07-02" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_905_edei--PreCommencementTenderOffer_c20210702__20210702_ztIK28diRqOd"><ix:nonNumeric contextRef="From2021-07-02to2021-07-02" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_90F_edei--PreCommencementIssuerTenderOffer_c20210702__20210702_zeTo3HoEZqJi"><ix:nonNumeric contextRef="From2021-07-02to2021-07-02" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Securities registered pursuant to Section
12(b) of the Act:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border: black 1pt solid; width: 40%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Title of each class</span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Trading Symbol(s)</span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 40%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Name of each exchange on which registered</span></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_908_edei--Security12bTitle_c20210702__20210702_z601O36kEga8"><ix:nonNumeric contextRef="From2021-07-02to2021-07-02" name="dei:Security12bTitle">Common stock, $0.001 par value</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_edei--TradingSymbol_c20210702__20210702_ziAb55W8Guek"><ix:nonNumeric contextRef="From2021-07-02to2021-07-02" name="dei:TradingSymbol">PLX</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_edei--SecurityExchangeName_c20210702__20210702_zHo1Wo4HHVqc"><ix:nonNumeric contextRef="From2021-07-02to2021-07-02" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NYSE American</ix:nonNumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3in 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif">Indicate</span> by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3in 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4in; text-align: right; text-indent: 0.5in">Emerging growth
company <span style="font-family: Wingdings"><span id="xdx_90D_edei--EntityEmergingGrowthCompany_c20210702__20210702_zLU8vtvRzQKf"><ix:nonNumeric contextRef="From2021-07-02to2021-07-02" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4in; text-align: center; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Item 1.01 <span style="font-size: 10pt">Entry
into a Material Definitive Agreement.</span></b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On July 2, 2021, Protalix BioTherapeutics, Inc., a Delaware corporation
(the &#8220;Company&#8221;) entered into an At The Market Offering Agreement (the &#8220;Sales Agreement&#8221;) with H.C. Wainwright
 &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;). Pursuant to the terms of the Sales Agreement, the Company
may sell from time to time through the Agent shares of the Company&#8217;s common stock having an aggregate offering price of up to $20,000,000
(the &#8220;Shares&#8221;). The Shares will be issued pursuant to the Company&#8217;s shelf registration statement on Form S-3 (Registration
No. 333-230604). The Company intends to use the net proceeds from the offering, after deducting the Agent&#8217;s commissions and the
Company&#8217;s offering expenses, for general corporate purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In accordance with the terms of the Sales Agreement, the Company
may offer and sell the Shares at any time and from time to time through the Agent. Sales of the Shares, if any, will be made by means
of transactions that are deemed to be &#8220;at the market&#8221; offerings as defined in Rule 415 under the Securities Act of 1933,
as amended, including block trades and sales made in ordinary brokers&#8217; transactions on the NYSE American or otherwise at market
prices prevailing at the time of the sale, at prices related to prevailing market prices or at negotiated prices. Under the terms of
the Sales Agreement, the Company may also sell Shares to the Agent as principal for its own account at a price to be agreed upon at the
time of sale. Any sale of Shares to the Agent as principal would be pursuant to the terms of a separate terms agreement between the Company
and the Agent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing description of the Sales Agreement in this report does
not purport to be complete and is qualified by reference to the full text of the Sales Agreement, which is filed as Exhibit 1.1 hereto.
The legal opinion and consent relating to the Shares are included as Exhibits 5.1 and 23.1, respectively, hereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Current Report on Form 8-K shall not constitute
an offer to sell or the solicitation of an offer to buy any Shares, nor shall there be any sale of Shares in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such
state or other jurisdiction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 1.02 <span style="font-size: 10pt">Termination of a Material Definitive Agreement.</span></b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On July 2, 2021, the Company terminated the ATM Equity Offering Sales
Agreement, dated October 1, 2020 (the &#8220;BofA Sales Agreement&#8221;) with BofA Securities, Inc. relating to the offer and sale of
the Company&#8217;s common stock having an aggregate offering price of up to $30,000,000. The Company sold a total of 3,296,123 shares
of common stock pursuant to the BofA Sales Agreement and the Company&#8217;s Prospectus Supplement filed October 1, 2020, for total gross
proceeds of approximately $13.8 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
8.01 Other Events.</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Forward-Looking Statements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">To the extent that statements in this Current Report on Form 8-K are
not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities
Litigation Reform Act of 1995. The terms &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221;
 &#8220;project,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should&#8221; and &#8220;intend,&#8221;
and other words or phrases of similar import are intended to identify forward-looking statements. These forward-looking statements are
subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the
statements made. These statements are based on the Company&#8217;s current beliefs and expectations as to such future outcomes. For a
discussion of other risks and uncertainties which could cause actual results to differ from those contained in the forward-looking statements,
see &#8220;Risk Factors&#8221; in the Company&#8217;s Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other
reports filed with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance upon any forward-looking
statements as the statements in this current report on Form 8-K are valid only as of the date hereof and disclaims any obligation to update
this information, except as may be required by law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
9.01 Financial Statements and Exhibits</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d) Exhibits:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 10%">Exhibit No.</td>
    <td style="width: 2%">&#160;</td>
    <td style="white-space: nowrap; text-align: center; width: 88%">Description</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><a href="tm2121219d1_ex1-1.htm" style="-sec-extract: exhibit">1.1</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm2121219d1_ex1-1.htm" style="-sec-extract: exhibit">At the Market Offering Agreement, dated July 2, 2021, between the Company and H.C. Wainwright &amp; Co., LLC</a></td></tr>
  <tr>
    <td style="vertical-align: top"><a href="tm2121219d1_ex5-1.htm" style="-sec-extract: exhibit">5.1</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm2121219d1_ex5-1.htm" style="-sec-extract: exhibit">Opinion of Mayer Brown LLP</a></td></tr>
  <tr>
    <td style="vertical-align: top"><a href="tm2121219d1_ex5-1.htm" style="-sec-extract: exhibit">23.1</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm2121219d1_ex5-1.htm" style="-sec-extract: exhibit">Consent of Mayer Brown LLP (included in Exhibit 5.1)</a></td></tr>
  <tr>
    <td style="vertical-align: top">104</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr>
    <td style="text-align: justify">Date: July 2, 2021</td>
    <td colspan="2" style="text-align: justify"><b>PROTALIX BIOTHERAPEUTICS, INC.</b></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="width: 50%; text-align: justify">&#160;</td>
    <td style="width: 4%; text-align: justify">By:</td>
    <td style="border-bottom: Black 1pt solid; width: 46%; text-align: justify">/s/ Dror Bashan</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name: Dror Bashan</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title: President and Chief Executive Officer</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: justify; text-indent: -3.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: justify; text-indent: -3.5in"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: justify; text-indent: -3.5in">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdsKgkAQhp/Adxj2Omq1w4WXSUVkISLR7aJjLOmOzG4HH6m3bFOiYWBO/ze/EBOxo61ukOGyzlMosO0a5RByrJHRlOgVyf4Qg685XrV1rIwbxh+YkGfQM8vpvPT7QfnQFqsY5Gom57NI+iZehJAdRfC9J2RqXaFxWjWgTAUZU8caneJ+/FCoFxlq+8HpjGw1mRjCqRzPb4hkGMGJHupJfLOQpokIJkMEYsd07742d+uohU2DrfeyI/rP4APcfUkX -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>tm2121219d1_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

                           <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
1.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Protalix
BioTherapeutics, Inc.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
Stock<BR>
($0.001 par value)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AT
THE MARKET OFFERING AGREEMENT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
2, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.C.
    Wainwright &amp; Co., LLC </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">430
    Park Avenue</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    York, New York 10022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    Agent</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Protalix
BioTherapeutics, Inc., a Delaware corporation (the &#8220;<U>Company</U>&#8221;), proposes, subject to the terms and conditions stated
herein, to issue and sell from time to time to or through H.C. Wainwright &amp; Co., LLC, as sales agent and/or principal (the &#8220;<U>Agent</U>&#8221;),
shares (the &#8220;<U>Shares</U>&#8221;) of the Company&#8217;s common stock, $0.001 par value (the &#8220;<U>Common Stock</U>&#8221;),
having an aggregate gross sales price not to exceed $20,000,000, on the terms set forth in this At The Market Offering Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company agrees that whenever it determines to sell Shares directly to the Agent as principal it will enter into a separate written Terms
Agreement (each, a &#8220;<U>Terms Agreement</U>&#8221;), in substantially the form of <U>Annex I</U> hereto, relating to such sale in
accordance with Section 2(k) hereof. References herein to &#8220;this Agreement&#8221; or to matters contained &#8220;herein&#8221; or
 &#8220;hereunder,&#8221; or words of similar import, mean this At The Market Offering Agreement and any applicable Terms Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has prepared and filed with the Securities and Exchange Commission (the &#8220;<U>Commission</U>&#8221;) a shelf registration
statement on Form S-3 (File No. 333-230604) covering the public offering and sale of certain securities of the Company, including the
Shares, under the Securities Act of 1933, as amended (the &#8220;<U>1933 Act</U>&#8221;), and the rules and regulations promulgated thereunder
(the &#8220;<U>1933 Act Regulations</U>&#8221;), which shelf registration statement was declared effective by the Commission on April
12, 2019. The &#8220;<U>Registration Statement</U>,&#8221; as of any time, means such registration statement as amended by any post-effective
amendments thereto at such time, including the exhibits and any schedules thereto at such time, the documents incorporated or deemed
by the Company to be incorporated by reference therein at such time pursuant to Item 12 of Form S-3 under the 1933 Act and the documents
otherwise deemed to be a part thereof as of such time pursuant to Rule 430B of the 1933 Act Regulations (&#8220;<U>Rule 430B</U>&#8221;);
<U>provided</U>, <U>however</U>, that the &#8220;Registration Statement&#8221; without reference to a time means such registration statement
as amended by any post-effective amendments thereto as of the time of the first contract of sale for the Shares, which time shall be
considered the &#8220;new effective date&#8221; of the Registration Statement with respect to the Shares within the meaning of paragraph
(f)(2) of Rule 430B (&#8220;<U>Rule 430B(f)(2</U>)&#8221;), including the exhibits and schedules thereto at such time, the documents
incorporated or deemed by the Company to be incorporated by reference therein at such time pursuant to Item 12 of Form S-3 under the
1933 Act and the documents otherwise deemed to be a part thereof as of such time pursuant to Rule 430B. The base prospectus filed as
part of such shelf registration statement, as amended in the form in which it has been filed most recently with the Commission in accordance
with Section 3(b) or 3(c) hereof, including the documents incorporated or deemed by the Company to be incorporated by reference therein
pursuant to Item 12 of Form S-3 under the 1933 Act, is referred to herein as the &#8220;<U>Base Prospectus</U>.&#8221; Promptly after
execution and delivery of this Agreement, the Company will prepare and file a prospectus supplement relating to the Shares in accordance
with the provisions of Rule 424(b) of the 1933 Act Regulations (&#8220;<U>Rule 424(b)</U>&#8221;). Such final prospectus supplement,
as amended by the prospectus supplement filed most recently with the Commission in accordance with Section 3(b), 3(c) or 3(n) hereof,
as the case may be, including the documents incorporated or deemed by the Company to be incorporated by reference therein pursuant to
Item 12 of Form S-3 under the 1933 Act, is referred to herein as the &#8220;<U>Prospectus Supplement</U>.&#8221; The Base Prospectus,
as amended by the Prospectus Supplement and any applicable pricing supplement thereto, in the forms of the Base Prospectus, the Prospectus
Supplement and any such pricing supplement are first furnished to the Agent for use in connection with the offering and sale of Shares,
are collectively referred to herein as the &ldquo;<U>Prospectus</U>.&rdquo; For purposes of this Agreement, all references to the Registration
Statement, any preliminary prospectus or the Prospectus or any amendment or supplement thereto shall be deemed to include the copy filed
with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval system (or any successor system) (&ldquo;<U>EDGAR</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used in this Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<U>Applicable
Time</U>&#8221; means, with respect to any offer and sale of Shares, the time immediately prior to the first contract of sale for such
Shares, or such other time as agreed by the Company and the Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<U>General
Disclosure Package</U>&#8221; means each Issuer General Use Free Writing Prospectus, if any, issued prior to the Applicable Time, the
most recent Prospectus filed with the Commission in accordance with Section 3(b), 3(c) or 3(n) hereof that is distributed to investors
prior to the Applicable Time and the number of Shares and the initial offering price per Share, all considered together.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<U>Issuer
Free Writing Prospectus</U>&#8221; means any &#8220;issuer free writing prospectus,&#8221; as defined in Rule 433 of the 1933 Act Regulations
(&#8220;<U>Rule 433</U>&#8221;), including, without limitation, any &#8220;free writing prospectus&#8221; (as defined in Rule 405) relating
to the Shares that is (i) required to be filed with the Commission by the Company, (ii) a &#8220;road show that is a written communication&#8221;
within the meaning of Rule 433(d)(8)(i), whether or not required to be filed with the Commission, or (iii) exempt from filing with the
Commission pursuant to Rule 433(d)(5)(i) because it contains a description of the Shares or of the offering thereof that does not reflect
the final terms, in each case in the form filed or required to be filed with the Commission or, if not required to be filed, in the form
retained in the Company&#8217;s records pursuant to Rule 433(g).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<U>Issuer
General Use Free Writing Prospectus</U>&#8221; means any Issuer Free Writing Prospectus approved by the Agent or, in the case of a specific
offer and sale of Shares, the Agent pursuant to Section 3(l) hereof that is furnished to the Agent, as the case may be, for general distribution
to investors, as evidenced by communications between the Company and the Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<U>Issuer
Limited Use Free Writing Prospectus</U>&#8221; means any Issuer Free Writing Prospectus that is not an Issuer General Use Free Writing
Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
references in this Agreement to financial statements and schedules and other information which is &#8220;contained,&#8221; &#8220;included,&#8221;
 &#8220;made,&#8221; &#8220;stated&#8221; or &#8220;referred to&#8221; (or other references of like import) in the Registration Statement,
any preliminary prospectus or the Prospectus shall be deemed to include all such financial statements and schedules and other information
incorporated or deemed by the Company to be incorporated by reference in the Registration Statement, any preliminary prospectus or the
Prospectus, as the case may be, prior to the Applicable Time relating to the particular Shares&#894; and all references in this Agreement
to amendments or supplements to the Registration Statement, any preliminary prospectus or the Prospectus shall be deemed to include the
filing of any document under the Securities Exchange Act of 1934, as amended (the &#8220;<U>1934 Act</U>&#8221;), and the rules and regulations
promulgated thereunder (the &#8220;<U>1934 Act Regulations</U>&#8221;) incorporated or deemed by the Company to be incorporated by reference
in the Registration Statement, such preliminary prospectus or the Prospectus, as the case may be, at or after the Applicable Time relating
to the particular Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations and Warranties</U>. (a) The Company represents
and warrants to the Agent at the date of this Agreement, each Registration Statement Amendment Date (as defined in Section 3(o) hereof),
each Company Periodic Report Date (as defined in Section 3(n) hereof), each Company Earnings Report Date (as defined in Section 3(o)
hereof), each Request Date (as defined in Section 3(o) hereof), each Applicable Time and each Settlement Date (as defined in Section
2(h) hereof) (collectively, a &#8220;<U>Representation Date</U>&#8221;), and agrees with the Agent, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Compliance
of the Registration Statement, the Prospectus and Incorporated Documents</U>. The Company meets the requirements for use of Form S-3
under the 1933 Act. The Registration Statement is a shelf registration statement and the Shares have been and remain eligible for registration
by the Company on such shelf registration statement. Each of the Registration Statement and any post-effective amendment thereto has
become effective under the 1933 Act. No stop order suspending the effectiveness of the Registration Statement or any post-effective amendment
thereto has been issued under the 1933 Act, no notice of objection of the Commission to the use of the Registration Statement or any
post-effective amendment thereto pursuant to Rule 401(g)(1) of the 1933 Act Regulations (&#8220;<U>Rule 401(g)(1)</U>&#8221;) has been
received by the Company, no order preventing or suspending the use of any preliminary prospectus or the Prospectus or any amendment or
supplement thereto has been issued and no proceedings for any of those purposes have been instituted or are pending or, to the Company&#8217;s
knowledge, contemplated. The Company has complied with each request (if any) from the Commission for additional information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the Registration Statement and any post-effective amendment thereto, at the time of its effectiveness and as of each deemed effective
date with respect to the Agent pursuant to Rule 430B(f)(2), complied in all material respects with the requirements of the 1933 Act and
the 1933 Act Regulations. Each of any preliminary prospectus and the Prospectus and any amendment or supplement thereto, at the time
it was filed with the Commission, complied in all material respects with the requirements of the 1933 Act and the 1933 Act Regulations
and is identical to the electronically transmitted copy thereof filed with the Commission pursuant to EDGAR, except to the extent permitted
by Regulation S-T.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
documents incorporated or deemed by the Company to be incorporated by reference in the Registration Statement, any preliminary prospectus
and the Prospectus, when they became effective or at the time they were or hereafter are filed with the Commission, complied and will
comply in all material respects with the requirements of the 1934 Act and the 1934 Act Regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Accurate
Disclosure</U>. Neither the Registration Statement nor any amendment thereto, at its effective time or at any Settlement Date, contained,
contains or will contain an untrue statement of a material fact or omitted, omits or will omit to state a material fact required to be
stated therein or necessary to make the statements therein not misleading. At each Applicable Time, neither (A) the General Disclosure
Package nor (B) any individual Issuer Limited Use Free Writing Prospectus, when considered together with the General Disclosure Package,
included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary
in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. Neither the Prospectus
nor any amendment or supplement thereto (including any prospectus wrapper), as of its issue date, at the time of any filing with the
Commission pursuant to Rule 424(b) or at any Settlement Date, included, includes or will include an untrue statement of a material fact
or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading. The documents incorporated or deemed by the Company to be incorporated by reference in the
Registration Statement, the General Disclosure Package and the Prospectus, at the time the Registration Statement became effective or
when such documents incorporated by reference were or hereafter are filed with the Commission, as the case may be, when read together
with the other information in the Registration Statement, the General Disclosure Package or the Prospectus, as the case may be, did not,
do not and will not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or
necessary to make the statements therein not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Issuer
Free Writing Prospectuses</U>. No Issuer Free Writing Prospectus conflicts or will conflict with the information contained in the Registration
Statement, any preliminary prospectus or the Prospectus or any amendment or supplement thereto, including any document incorporated by
reference therein, that has not been superseded or modified.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Reserved].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Company
Not Ineligible Issuer</U>. (A) At the time of filing of the Registration Statement and any post-effective amendment thereto, (B) at the
earliest time thereafter that the Company or another offering participant made a <I>bona fide </I>offer (within the meaning of Rule 164(h)(2)
of the 1933 Act Regulations) of the Shares, (C) at the date of this Agreement and any Terms Agreement and (D) at each Applicable Time,
the Company was not and is not an &#8220;ineligible issuer,&#8221; as defined in Rule 405, without taking account of any determination
by the Commission pursuant to Rule 405 that it is not necessary that the Company be considered an ineligible issuer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Independent
Accountants</U>. Kesselman &amp; Kesselman, a member of PricewaterhouseCoopers International Limited, who has certified the financial
statements and supporting schedules included in the Registration Statement, the General Disclosure Package and the Prospectus is an independent
public accountant as required by the 1933 Act, the 1933 Act Regulations, the 1934 Act, the 1934 Act Regulations and the Public Company
Accounting Oversight Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Financial
Statements&#894; Non-GAAP Financial Measures</U>. The financial statements of the Company included in the Registration Statement, the
General Disclosure Package and the Prospectus, together with the related schedules and notes, present fairly in all material respects
the financial position of the Company and its consolidated subsidiaries at the dates indicated and the statement of operations, stockholders&#8217;
equity and cash flows of the Company and its consolidated subsidiaries for the periods specified; said financial statements have been
prepared in conformity with U.S. generally accepted accounting principles (&#8220;<U>GAAP</U>&#8221;) applied on a consistent basis throughout
the periods involved. The financial statements of the businesses acquired or proposed to be acquired, if any, included in the Registration
Statement, the General Disclosure Package and the Prospectus present fairly in all material respects the information set forth therein,
have been prepared in conformity with GAAP applied on a consistent basis and otherwise have been prepared in accordance with, in the
case of businesses acquired or to be acquired, the applicable financial statement requirements of Rule 3-05. Any pro forma financial
statements and the related notes thereto included in the Registration Statement, the General Disclosure Package and the Prospectus present
fairly in all material respects the information shown therein, have been prepared in accordance with the Commission&#8217;s rules and
guidelines with respect to pro forma financial statements and have been properly compiled on the bases described therein, and the assumptions
used in the preparation thereof are reasonable and the adjustments used therein are appropriate to give effect to the transactions and
circumstances referred to therein. Except as included in the Registration Statement, the General Disclosure Package and the Prospectus,
no historical or pro forma financial statements or supporting schedules are required to be included in the Registration Statement, any
preliminary prospectus or the Prospectus under the 1933 Act or the 1933 Act Regulations. The interactive data in eXtensible Business
Reporting Language incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus fairly
presents in all material respects the required information and has been prepared in accordance with the Commission's rules and guidelines
applicable thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(viii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No
Material Adverse Change</U>. Except as stated in the Registration Statement, the General Disclosure Package and the Prospectus, since
the respective dates as of which information is given in the Registration Statement, the General Disclosure Package or the Prospectus,
(A) there has been no material adverse change in the condition, financial or otherwise, or in the earnings, business affairs or business
prospects of the Company and its subsidiaries considered as one enterprise, whether or not arising in the ordinary course of business
(a &#8220;<U>Material Adverse Change</U>&#8221;), (B) there have been no transactions entered into by the Company or any of its subsidiaries,
other than those in the ordinary course of business, which are material with respect to the Company and its subsidiaries considered as
one enterprise, and (C) there has been no dividend or distribution of any kind declared, paid or made by the Company on any class or
series of its capital stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ix)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Good
Standing of the Company</U>. The Company has been duly incorporated and is validly existing as a corporation in good standing under the
laws of the State of Delaware and has all requisite corporate power and authority to own, lease and operate its properties and to conduct
its business as described in the Registration Statement, the General Disclosure Package and the Prospectus and to enter into and perform
its obligations under, and to consummate the transactions contemplated in, this Agreement. The Company is duly qualified as a foreign
corporation to transact business and is in good standing in each jurisdiction in which such qualification is required, whether by reason
of the ownership or leasing of property or the conduct of business, except where the failure so to qualify or to be in good standing
would not, singly or in the aggregate, reasonably be expected to result in a material adverse effect in (A) the condition, financial
or otherwise, or in the earnings, business affairs or business prospects of the Company and its subsidiaries considered as one enterprise,
whether or not arising in the ordinary course of business, or (B) the ability of the Company to enter into and perform any of its obligations
under, or to consummate any of the transactions contemplated in, this Agreement (collectively, a &#8220;<U>Material Adverse Effect</U>&#8221;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Good
Standing of Subsidiaries</U>. Each &#8220;significant subsidiary&#8221; of the Company (as such term is defined in Rule 1-02 of Regulation
S-X), if any (each, a &#8220;<U>Significant Subsidiary</U>&#8221; and, collectively, the &#8220;<U>Significant Subsidiaries</U>&#8221;)
has been duly organized and is validly existing in good standing under the laws of the jurisdiction of its incorporation or organization,
has all requisite power and authority to own, lease and operate its properties and to conduct its business as described in the Registration
Statement, the General Disclosure Package and the Prospectus and is duly qualified to transact business and is in good standing in each
jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business,
except where the failure so to qualify or to be in good standing would not, singly or in the aggregate, reasonably be expected to result
in a Material Adverse Effect. Except as described in the Registration Statement, the General Disclosure Package and the Prospectus, all
of the outstanding shares of capital stock or other equity interests in each Significant Subsidiary have been duly authorized and validly
issued, are fully paid and non-assessable and are owned by the Company, directly or through other subsidiaries of the Company, free and
clear of any security interest, mortgage, pledge, lien, encumbrance, claim or equity. None of the outstanding shares of capital stock
of or other equity interests in any Significant Subsidiary were issued in violation of the preemptive or similar rights of any securityholder
of such Significant Subsidiary or any other person or entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Capitalization&#894;
Listing of Common Stock</U>. The authorized, issued and outstanding shares of capital stock of the Company are as set forth in the Registration
Statement and the Prospectus (except for subsequent issuances, if any, pursuant to this Agreement, pursuant to reservations, agreements
or employee benefit plans referred to in the Registration Statement, the General Disclosure Package and the Prospectus or pursuant to
the exercise of convertible securities or options referred to in the Registration Statement, the General Disclosure Package and the Prospectus).
The outstanding shares of capital stock of the Company have been duly authorized and validly issued and are fully paid and non-assessable.
None of the outstanding shares of capital stock of the Company were issued in violation of the preemptive or other similar rights of
any securityholder of the Company or any other person or entity. Except as stated in the Registration Statement, the General Disclosure
Package and the Prospectus, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character
whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any individual
or entity any right to subscribe for or acquire, any shares of Common Stock, or contracts, commitments, understandings or arrangements
by which the Company is or may become bound to issue additional shares of Common Stock or securities convertible into or exercisable or
exchangeable for Common Stock. The Company&#8217;s Common Stock has been registered pursuant to Section
12(b) of the 1934 Act and the Shares have been approved for listing, subject to official notice of issuance, on the NYSE American LLC
(the &#8220;<U>NYSE American</U>&#8221;), and the Company has taken no action designed to, or likely to have the effect of, terminating
the registration of the Common Stock under the 1934 Act or the listing of the Common Stock on the NYSE American, nor has the Company
received any notification that the Commission or the NYSE American is contemplating terminating such registration or listing, except
as stated in the Registration Statement, the General Disclosure Package and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Authorization
of this Agreement</U>. This Agreement has been duly authorized, executed and delivered by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xiii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Authorization
and Description of Shares</U>. The Shares have been duly authorized for issuance and sale by the Company pursuant to this Agreement and,
when issued and delivered by the Company pursuant to this Agreement against payment of the consideration set forth in this Agreement,
will be validly issued, fully paid and non-assessable. The issuance of the Shares is not subject to the preemptive or other similar rights
of any securityholder of the Company or any other person or entity. The Common Stock conforms to all statements relating thereto contained
in the Registration Statement, the General Disclosure Package and the Prospectus and such statements conform to the rights set forth
in the instruments defining the same. No holder of Shares will be subject to personal liability by reason of being such a holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xiv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Registration
Rights</U>. There are no persons with registration rights or other similar rights to have any securities registered for sale pursuant
to the Registration Statement or otherwise registered for sale or sold by the Company under the 1933 Act pursuant to this Agreement,
other than those rights that have been disclosed in the Registration Statement, the General Disclosure Package and the Prospectus and
have been waived.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Absence
of Violations, Defaults and Conflicts</U>. Neither the Company nor any of its subsidiaries are (A) in violation of its charter, by-laws
or similar organizational document, (B) in default in the performance or observance of any obligation, agreement, covenant or condition
contained in any contract, indenture, mortgage, deed of trust, loan or credit agreement, note, lease or other agreement or instrument
to which the Company or any of its subsidiaries are a party or by which it or any of them may be bound or to which any of the properties,
assets or operations of the Company or any of its subsidiaries are subject (collectively, &#8220;<U>Agreements and Instruments</U>&#8221;),
except for such defaults that would not, singly or in the aggregate, reasonably be expected to result in a Material Adverse Effect, or
(C) in violation of any law, statute, rule, regulation, judgment, order, writ or decree of any arbitrator, court, governmental body,
regulatory body, administrative agency or other authority, body or agency having jurisdiction over the Company or any of its subsidiaries
or any of their respective properties, assets or operations (each, a &#8220;<U>Governmental Entity</U>&#8221;), except for such violations
that would not, singly or in the aggregate, reasonably be expected to result in a Material Adverse Effect. The execution, delivery and
performance of this Agreement and the consummation of the transactions contemplated herein and in the Registration Statement, the General
Disclosure Package and the Prospectus (including the issuance and sale of Shares and the use of the proceeds from the sale thereof as
described therein under the caption &#8220;Use of Proceeds&#8221;) and compliance by the Company with its obligations hereunder have
been duly authorized by all requisite action and do not and will not, whether with or without the giving of notice or passage of time
or both, conflict with or constitute a breach of, or default or Repayment Event (as defined below) under, or result in the creation or
imposition of any lien, charge or encumbrance upon any properties, assets or operations of the Company or any of its subsidiaries pursuant
to, the Agreements and Instruments (except for such conflicts, breaches, defaults or Repayment Events or liens, charges or encumbrances
that would not, singly or in the aggregate, reasonably be expected to result in a Material Adverse Effect), nor will such action result
in any violation of the provisions of (a) the charter, by-laws or similar organizational document of the Company or any of its subsidiaries
or (b) any law, statute, rule, regulation, judgment, order, writ or decree of any Governmental Entity, except in the case of clause (b),
as would not singly or in the aggregate, reasonably be expected to have a Material Adverse Effect. As used herein, a &#8220;<U>Repayment
Event</U>&#8221; means any event or condition which gives the holder of any note, debenture or other financing instrument (or any person
acting on such holder&#8217;s behalf) the right to require the repurchase, redemption or repayment of all or a portion of the related
financing by the Company or any of its subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xvi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Absence
of Labor Dispute</U>. No labor dispute with the employees of the Company or any of its subsidiaries exists or, to the knowledge of the
Company, is imminent, which could, singly or in the aggregate, reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xvii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Absence
of Proceedings</U>. Except as stated in the Registration Statement, the General Disclosure Package and the Prospectus, there is no action,
suit, proceeding, inquiry or investigation before or brought by any Governmental Entity now pending or, to the knowledge of the Company,
threatened, against or affecting the Company or any of its subsidiaries, which could, singly or in the aggregate, reasonably be expected
to result in a Material Adverse Effect. The aggregate of all pending legal or governmental proceedings to which the Company or any of
its subsidiaries are a party or of which any of their respective properties, assets or operations are the subject which are not described
in the Registration Statement, the General Disclosure Package and the Prospectus, including ordinary routine litigation incidental to
the business, would not, singly or in the aggregate, reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xviii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Accuracy
of Exhibits</U>. There are no contracts or documents which are required to be described in all material respects in the Registration
Statement, any preliminary prospectus or the Prospectus or to be filed as exhibits to the Registration Statement which have not been
so described and filed as required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xix)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Absence
of Further Requirements</U>. No filing with, or authorization, approval, consent, license, order, registration, qualification or decree
of, any Governmental Entity is necessary or required for the Company&#8217;s due authorization, execution and delivery of, or performance
of its obligations under, this Agreement or for the offering, issuance, sale or delivery of Shares or the consummation of the transactions
contemplated in this Agreement except such as have been already obtained or as may be required under the 1933 Act, the 1933 Act Regulations,
the rules of the NYSE American, the securities laws of any state or non-U.S. jurisdiction or the rules of Financial Industry Regulatory
Authority, Inc. (&#8220;<U>FINRA</U>&#8221;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xx)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Possession
of Licenses and Permits</U>. The Company and its subsidiaries possess and are in compliance in all material respects with the terms of
all licenses, approvals, orders, certificates, permits and other authorizations (collectively, &#8220;<U>Licenses</U>&#8221;) issued
by all applicable authorities, including, without limitation, all such Licenses required by the U.S. Food and Drug Administration or
any component thereof and/or by any other U.S. state, local or foreign government or drug regulatory agency (collectively, the &#8220;<U>Regulatory
Agencies</U>&#8221;) necessary to conduct their respective businesses as described in the Registration Statement, the General Disclosure
Package and the Prospectus, as applicable, and neither the Company nor any such subsidiary has received any notice of proceedings (or
otherwise) relating to the revocation or modification of, or non-compliance with, any such License that, singly or in the aggregate,
if the subject of an unfavorable decision, ruling or finding, would reasonably be expected to have a Material Adverse Effect, except
as set forth or contemplated in the Registration Statement, the General Disclosure Package and the Prospectus, and all such Licenses
are in full force and effect. The Company and its subsidiaries are in compliance with all statutes, rules and regulations applicable
to the ownership, testing, development, manufacture, packaging, processing, use, distribution, storage, import, export or disposal of
any product manufactured or distributed by them, except where such noncompliance would not, singly or in the aggregate, reasonably be
expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xxi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Title
to Property</U>. The Company and its subsidiaries have good and marketable title to all real property owned by them and good title to
all other properties owned by them that is material to the business of the Company and its subsidiaries, in each case, free and clear
of all mortgages, pledges, liens, security interests, claims, restrictions or encumbrances of any kind except such as (A) are described
in the Registration Statement, the General Disclosure Package and the Prospectus or (B) do not, singly or in the aggregate, materially
affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company
or any of its subsidiaries. All of the leases and subleases material to the business of the Company and its subsidiaries, considered
as one enterprise, and under which the Company or any of its subsidiaries holds properties described in the Registration Statement, the
General Disclosure Package or the Prospectus, are in full force and effect, and neither the Company nor any such subsidiary has any notice
of any material claim of any sort that has been asserted by anyone adverse to its rights under any of the leases or subleases mentioned
above or affecting or questioning its rights to the continued possession of the leased or subleased premises under any such lease or
sublease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xxii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Possession
of Intellectual Property</U>. The Company and its subsidiaries own, possess, have a valid license or otherwise have adequate rights to
use, on reasonable terms, all patents, trademarks, service marks, trade names, Internet domain names, copyrights and copyrightable works,
licenses, inventions, trade secrets, technology, and software, data, know-how (whether or not patentable) and other intellectual property
or proprietary rights (including all registrations and applications for registration and renewals of, and all goodwill associated with,
the foregoing) (collectively, the &#8220;<U>Intellectual Property</U>&#8221;) necessary for the conduct of the Company&#8217;s and its
subsidiaries&#8217; businesses as now conducted and intended to be conducted. Except as would not reasonably be expected to have, singly
or in the aggregate, a Material Adverse Effect: (a) there are no rights of third parties to any such Intellectual Property; (b) to the
Company&#8217;s knowledge, there is no material infringement, misappropriation or other violation by third parties of any such Intellectual
Property; (c) there is no pending or, to the Company&#8217;s knowledge, threatened action, suit, proceeding or claim by others challenging
the Company&#8217;s or its subsidiaries&#8217; rights in or to any such Intellectual Property, and the Company is unaware of any facts
which would form a reasonable basis for any such claim; (d) such Intellectual Property is subsisting and, to the knowledge of the Company,
valid and enforceable, and there is no pending or, to the Company&#8217;s knowledge, threatened action, suit, proceeding or claim by
others challenging the validity, enforceability or scope of any such Intellectual Property, and the Company is unaware of any facts which
would form a reasonable basis for any such claim; (e) to the knowledge of the Company, the Company and its subsidiaries do not engage
in any activity that, and there is no pending or, to the Company&#8217;s knowledge, threatened action, suit, proceeding or claim by others
that the Company or any of its subsidiaries, infringes, misappropriates or otherwise violates any Intellectual Property or other proprietary
rights of others, and the Company is unaware of any other fact which would form a reasonable basis for any such claim; (f) to the Company&#8217;s
knowledge there is no U.S. patent or published U.S. patent application which contains claims that have (or may have) priority over or
dominate (or may dominate) any Intellectual Property described in the Registration Statement, the General Disclosure Package and the
Prospectus as being owned by or licensed to the Company or its subsidiaries or that interferes with the issued or pending claims of any
such Intellectual Property; and (g) there is no prior art of which the Company is aware that may render any U.S. patent held by the Company
or its subsidiaries invalid or any U.S. patent application held by the Company or its subsidiaries unpatentable that has not been disclosed
to the U.S. Patent and Trademark Office. Each current and former employee and officer of the Company and its subsidiaries or any Affiliate
has executed a valid written agreement with the Company or such subsidiary or Affiliate regarding confidentiality and the assignment
of all proprietary information and inventions created by such person. Each current and former consultant to the Company and its subsidiaries
or any Affiliate that may be involved in the generation of Intellectual Property has executed a valid written agreement with the Company
or such subsidiary or Affiliate regarding confidentiality and the assignment of all proprietary information and inventions created by
such person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xxiii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Environmental
Laws</U>. Except as described in the Registration Statement, the General Disclosure Package and the Prospectus or would not, singly or
in the aggregate, result in a Material Adverse Effect, the Company and each of its subsidiaries (a) are not in violation of any and all
applicable foreign, federal, state and local laws and regulations (including common law and any binding judicial or administrative decisions)
relating to the protection of human health and safety, the environment (including sustainability and the protection of habitats or ecosystems)
or hazardous, toxic or radioactive substances or wastes, pollutants or contaminants (including greenhouse gases) (&#8220;<U>Environmental
Laws</U>&#8221;); (b) have received and are in compliance with all permits, licenses or other approvals required of them under applicable
Environmental Laws to conduct their respective businesses; and (c) have not received any notice, demand or claim alleging any actual
or potential noncompliance with or liability under any Environmental Law or permit, license or approval thereunder and are not aware
of any fact or circumstance that would reasonably be expected to form the basis of any such notice, demand or claim. Except as set forth
in the Registration Statement, the General Disclosure Package and the Prospectus, neither the Company nor any of its subsidiaries has
been named as a &#8220;potentially responsible party&#8221; under the Comprehensive Environmental Response, Compensation and Liability
Act of 1980, as amended. In the ordinary course of its business, the Company periodically reviews the effect of Environmental Laws on
the business, operations and properties of the Company and its subsidiaries, in the course of which it identifies and evaluates associated
costs and liabilities (including, without limitation, any capital or operating expenditures required for clean-up, closure of properties
or compliance with Environmental Laws or any permit, license, registration or approval, any related constraints on operating activities
and any potential liabilities to third parties); on the basis of such review, the Company has reasonably concluded that such associated
costs and liabilities would not, singly or in the aggregate, reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xxiv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Accounting
Controls and Disclosure Controls</U>. The Company maintains effective internal control over financial reporting (as defined under Rule
13-a15 and Rule 15d-15 of the 1934 Act Regulations) and a system of internal accounting controls sufficient to provide reasonable assurances
that: (A) transactions are executed in accordance with management&#8217;s general or specific authorization; (B) transactions are recorded
as necessary to permit preparation of financial statements in conformity with GAAP and to maintain accountability for assets; (C) access
to assets is permitted only in accordance with management&#8217;s general or specific authorization; (D) the recorded accountability
for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences;
and (E) the interactive data in eXtensible Business Reporting Language incorporated by reference in the Registration Statement, the General
Disclosure Package and the Prospectus fairly presents in all material respects the required information and is prepared in accordance
with the Commission&#8217;s rules and guidelines applicable thereto. Except as described in the Registration Statement, the General Disclosure
Package and the Prospectus, since the end of the Company&#8217;s most recent audited fiscal year, there has been (1) no material weakness
in the Company&#8217;s internal control over financial reporting (whether or not remediated) and (2) no change in the Company&#8217;s
internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s
internal control over financial reporting. The Company maintains an effective system of disclosure controls and procedures (as defined
in Rule 13a-15 and Rule 15d-15 of the 1934 Act Regulations) that are designed to ensure that the information required to be disclosed
by the Company in the reports that it files or submits under the 1934 Act is recorded, processed, summarized and reported within the
time periods specified in the Commission&#8217;s rules and forms, and is accumulated and communicated to the Company&#8217;s management,
including its principal executive officer or officers and principal financial officer or officers, as appropriate, to allow timely decisions
regarding disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xxv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Compliance
with the Sarbanes-Oxley Act</U>. There is and has been no failure on the part of the Company or any of the Company&#8217;s directors
or officers, in their capacities as such, to comply in all material respects with any provision of the Sarbanes-Oxley Act of 2002, as
amended, and the rules and regulations promulgated in connection therewith, including, without limitation, Section 402 related to loans
and Sections 302 and 906 related to certifications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xxvi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Payment
of Taxes</U>. All United States federal, state, local and non-U.S. tax returns of the Company and its subsidiaries required by law to
be filed have been filed, except where the failure to do so would not, singly or in the aggregate, reasonably be expected to have a Material
Adverse Effect and all taxes shown by such returns or otherwise assessed, which are due and payable, have been paid, except assessments
against which appeals have been or will be promptly taken and as to which adequate reserves have been provided in accordance with GAAP
by the Company. Except as otherwise disclosed in the Registration Statement or the Prospectus, no tax deficiency has been determined
adversely to the Company which has had, or would reasonably be expected to have, individually or in the aggregate, a Material Adverse
Effect. The Company has no knowledge of any federal, state or other governmental tax deficiency, penalty or assessment which has been
or might be asserted or threatened against it which would reasonably be expected to have a Material Adverse Effect. The charges, accruals
and reserves on the books of the Company in respect of any income and corporation tax liability for any years not finally determined
are adequate to meet any assessments or re-assessments for additional income tax for any years not finally determined, except to the
extent of any inadequacy that would not, singly or in the aggregate, reasonably expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xxvii)&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Insurance</U>.
The Company and its subsidiaries carry or are entitled to the benefits of insurance, with financially sound and reputable insurers, in
such amounts and covering such risks as is generally maintained by companies of established repute engaged in the same or similar business,
and all such insurance is in full force and effect. The Company has no reason to believe that it or any of its subsidiaries will not
be able (A) to renew its existing insurance coverage as and when such policies expire or (B) to obtain comparable coverage from similar
institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not, singly or in the
aggregate, reasonably be expected to result in a Material Adverse Effect. Neither of the Company nor any of its subsidiaries has been
denied any insurance coverage which it has sought or for which it has applied <FONT STYLE="background-color: white">where such denial
would or has resulted in a Material Adverse Effect</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xxviii)&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Investment
Company Act</U>. The Company is not required, and upon the issuance and sale of the Shares as contemplated herein and the application
of the net proceeds therefrom as described in the Registration Statement, the General Disclosure Package and the Prospectus will not
be required, to register as an &#8220;investment company&#8221; under the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xxix)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Absence
of Manipulation</U>. Neither the Company nor any affiliate of the Company has taken, nor will the Company or any such affiliate take,
directly or indirectly, any action which is designed, or would be expected, to cause or result in, or which constitutes, the stabilization
or manipulation of the price of any security of the Company to facilitate the sale or resale of any Shares or to result in a violation
of Regulation M under the 1934 Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xxx)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Foreign
Corrupt Practices Act</U>. None of the Company, any of its subsidiaries or, to the knowledge of the Company, any director, officer, agent,
employee, affiliate or other person acting on behalf of the Company or any of its subsidiaries is aware of or has taken any action, directly
or indirectly, that would result in a violation by such persons of either (A) the Foreign Corrupt Practices Act of 1977, as amended,
and the rules and regulations thereunder (the &#8220;<U>FCPA</U>&#8221;), including, without limitation, making use of the mails or any
means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment, promise to pay or authorization of the
payment of any money, or other property, gift, promise to give, or authorization of the giving of anything of value to any &#8220;foreign
official&#8221; (as such term is defined in the FCPA) or any foreign political party or official thereof or any candidate for foreign
political office, in contravention of the FCPA or (B) the U.K. Bribery Act 2010 (the &#8220;<U>Bribery Act</U>&#8221;), and the Company,
its subsidiaries and, to the knowledge of the Company, its other affiliates have conducted their businesses in compliance with the FCPA
and the Bribery Act and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to
continue to ensure, continued compliance therewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xxxi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Money
Laundering Laws</U>. The operations of the Company and its subsidiaries are and have been conducted at all times in compliance with applicable
financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money
laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines,
issued, administered or enforced by any Governmental Entity (collectively, the &#8220;<U>Money Laundering Laws</U>&#8221;). No action,
suit or proceeding by or before any Governmental Entity involving the Company or any of its subsidiaries with respect to the Money Laundering
Laws is pending or, to the knowledge of the Company, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xxxii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>OFAC</U>.
None of the Company, any of its subsidiaries or, to the knowledge of the Company, any director, officer, agent, employee, affiliate or
other person acting on behalf of the Company or any of its subsidiaries is (A) an individual or entity (&#8220;<U>Person</U>&#8221;)
currently the subject or target of any sanctions administered or enforced by the United States Government, including, without limitation
the U.S. Department of the Treasury&#8217;s Office of Foreign Assets Control, the United Nations Security Council, the European Union,
Her Majesty&#8217;s Treasury, or other relevant sanctions authority (collectively, &#8220;<U>Sanctions</U>&#8221;), or (B) located, organized
or resident in a country or territory that is the subject of Sanctions. The Company will not, directly or indirectly, use the proceeds
of the sale of the Shares, or lend, contribute or otherwise make available such proceeds to any of its subsidiaries, joint venture partners
or other Persons, to fund any activities of or business with any Person, or in any country or territory, that, at the time of such funding,
is the subject of Sanctions or in any other manner that will result in a violation by any Person (including any Person participating
in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xxxiii)&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Statistical
and Market-Related Data</U>. Nothing has come to the attention of the Company that has caused the Company to believe that the statistical
and market-related data included in the Registration Statement, the General Disclosure Package or the Prospectus is not based on or derived
from sources that are reliable and accurate in all material respects and, to the extent required, the Company has obtained the written
consent to the use of such data from such sources</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xxxiv)&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No
Commissions</U>. Neither the Company nor any of its subsidiaries are a party to any contract, agreement or understanding with any person
(other than as contemplated by this Agreement) that would give rise to a valid claim against the Company, any of its subsidiaries or
the Agent for a brokerage commission, finder&#8217;s fee or like payment in connection with the offering and sale of any Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xxxv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Not
an Actively-Traded Security</U>. Unless the Company informs the Agent otherwise, the Common Stock is not an &#8220;actively-traded security&#8221;
exempted from the requirements of Rule 101 of Regulation M under the 1934 Act by subsection (c)(1) of such rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xxxvi)&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Cybersecurity
and Data Protection</U>. (A) To the knowledge of the Company, there has been no security breach or incident, unauthorized access or disclosure,
or other compromise of or relating to, the Company&#8217;s or its subsidiaries&#8217; information technology and computer systems, networks,
hardware, software, data and databases (including the data and information of their respective patients, customers, employees, suppliers,
vendors and any third party data maintained, processed or stored by the Company or its subsidiaries, and any such data processed or stored
by third parties on behalf of the Company or its subsidiaries), equipment or technology (collectively, &#8220;<U>IT Systems and Data</U>&#8221;),
(B)&nbsp;neither the Company nor its subsidiaries have been notified of, and have no knowledge of any event or condition that would result
in, any security breach or incident, unauthorized access or disclosure of or other compromise to their IT Systems and Data and (C) the
Company and its subsidiaries have implemented appropriate controls, policies, procedures, and technological safeguards to maintain and
protect the integrity, continuous operation, redundancy, disaster recovery and security of their IT Systems and Data consistent with
industry standards and practices, or as required by applicable data protection laws, Healthcare Laws and regulatory standards, except
with respect to clauses (A) and (B), for any such security breach or incident, unauthorized access or disclosure, or other compromises,
as would not, individually or in the aggregate, have a Material Adverse Effect, or with respect to clause (C), where the failure to do
so would not, individually or in the aggregate, have a Material Adverse Effect. The Company and its subsidiaries are presently in compliance
in all material respects with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator
or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of the IT
Systems and Data, including the collection, use, transfer, processing, disposal, disclosure, handling, storage and analysis of personally
identifiable information, protected health information, consumer information and other confidential information of the Company, its subsidiaries
and any third parties in their possession, and the protection of such IT Systems and Data from unauthorized use, access, misappropriation
or modification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xxxvii)&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Regulatory Matters</U>. The Company and each of its
subsidiaries: (a) are and have been in material compliance with applicable health care laws, including, without limitation, the Federal
Food, Drug and Cosmetic Act (21 U.S.C. &sect; 301 et seq.), the Federal Anti-kickback Statute (42 U.S.C. &sect; 1320a-7b(b)), Physician
Payment Sunshine Act (42 U.S.C. &sect; 1320a-7h), the civil False Claims Act (31 U.S.C. &sect;&sect; 3729 et seq.), the administrative
False Claims Law (42 U.S.C. &sect; 1320a-7b(a)), the Anti-Inducement Law (42 U.S.C. &sect; 1320a-7a(a)(5)), the Health Insurance Portability
and Accountability Act of 1996 (42 U.S.C. &sect; 1320d et seq.), as amended by the Health Information Technology for Economic and Clinical
Health Act of 2009, the exclusion laws, Social Security Act &sect; 1128 (42 U.S.C. &sect; 1320a-7), Medicare (Title XVIII of the Social
Security Act), Medicaid (Title XIX of the Social Security Act) and the regulations promulgated pursuant to such laws, and comparable
state laws, and all other local, state, federal, national, supranational and foreign laws, manual provisions, policies and administrative
guidance relating to the regulation of the Company and its subsidiaries (collectively, &#8220;<U>Health Care Laws</U>&#8221;); (b) have
not received notice of any ongoing claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action
from any Regulatory Agency or third party alleging that any product operation or activity is in material violation of any Health Care
Laws and has no knowledge that any such Regulatory Agency or third party is considering any such claim, litigation, arbitration, action,
suit, investigation or proceeding; and (c) are not a party to any corporate integrity agreement, deferred prosecution agreement, monitoring
agreement, consent decree, settlement order or similar agreements or have any reporting obligations pursuant to any such agreement, plan
or correction or other remedial measure entered into with any governmental authority. Neither the Company nor its subsidiaries or any
of their officers, directors, employees, agents or contractors has been or is currently debarred, suspended or excluded from participation
in the Medicare and Medicaid programs or any other state or federal health care program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xxxviii)&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Preclinical
and Clinical Studies and Tests</U>. The preclinical tests and clinical trials that are described in, or the results of which are referred
to in, the Registration Statement, the General Disclosure Package and the Prospectus, as applicable, were and, if still pending, are
being conducted in all material respects in accordance with protocols filed with the appropriate Regulatory Agencies for each such test
or trial, as the case may be, and with standard medical and scientific research procedures and all applicable statutes, directives, rules
and regulations of the Regulatory Agencies, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and
regulations promulgated thereunder; each description of such tests and trials, and the results thereof, contained in the Registration
Statement, the General Disclosure Package and the Prospectus, as applicable, is accurate and complete in all material respects and fairly
presents the data about and derived from such tests and trials, and the Company has no knowledge of any other studies or tests or modifications,
the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration
Statement, the General Disclosure Package and the Prospectus, as applicable; neither the Company nor its subsidiaries has received any
notices or other correspondence from any Regulatory Agency requiring the termination, suspension or modification of any clinical trials;
and each of the Company and its subsidiaries has operated and currently is in compliance in all material respects with all applicable
rules and regulations of the Regulatory Agencies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xxxix)&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No
Safety Notices</U>. (i) There have been no recalls, field notifications, field corrections, market withdrawals or replacements, warnings,
 &#8220;dear doctor&#8221; letters, investigator notices, safety alerts or other notice of action relating to an alleged lack of safety,
efficacy, or regulatory compliance of the Company&#8217;s or its subsidiaries&#8217; products and product candidates (&#8220;<U>Safety
Notices</U>&#8221;), except as would not reasonably be expected to, singly or in the aggregate, result in a Material Adverse Effect,
and (ii) there are no facts that would be reasonably likely to result in (x) a Safety Notice with respect to the Company&#8217;s or its
subsidiaries&#8217; products and product candidates, or (y) a termination or suspension of testing of any of the Company&#8217;s or its
subsidiaries&#8217; products and product candidates, except, in each of cases (x) or (y) such as would not reasonably be expected to,
singly or in the aggregate, result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
certificate signed by any officer or other authorized signatory of the Company and delivered to the Agent or to counsel for the Agent
shall be deemed a representation and warranty by the Company to the Agent as to the matters covered thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Sale and Delivery of Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the terms and conditions set forth herein, the Company agrees to issue and sell Shares through the Agent acting as sales agent or
directly to the Agent acting as principal from time to time. Sales of the Shares, if any, through the Agent acting as sales agent or
directly to the Agent acting as principal will be made by means of transactions that are deemed to be &#8220;at-the-market&#8221; offerings
as defined in Rule 415 under the 1933 Act, including block trades, ordinary brokers&#8217; transactions on the NYSE American or otherwise
at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices, or by any other
method permitted by law. If any sales are made pursuant to this Agreement which are not made in &#8220;at-the-market&#8221; offerings
as defined in Rule 415 under the 1933 Act, the Company shall file a prospectus supplement describing the terms of such transaction, the
amount of Shares sold, the price thereof, the Agent&#8217;s compensation and such other information as may be required pursuant to Rule
424 and Rule 430B, as applicable, within the time required by Rule 424.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Shares are to be sold to the Agent on an agented basis on any day that the NYSE American is open for trading (each, a &#8220;<U>Trading
Day</U>&#8221;) on which (i) the Company has instructed the Agent to make such sales and (ii) the Company has satisfied its covenants
and conditions specified in Sections 4 and 5 hereof. On any Trading Day, the Company may sell Shares through the Agent and, if it determines
to do so, shall instruct the Agent by telephone (confirmed promptly by email, which confirmation will be promptly acknowledged by the
Agent) as to the maximum number of Shares to be sold on such Trading Day and the minimum price per Share at which such Shares may be
sold. Subject to the terms and conditions specified herein (including, without limitation, the accuracy of the representations and warranties
of the Company and the performance by the Company of its covenants and other obligations, contained herein and the satisfaction of the
additional conditions specified in Section 5 hereof), </FONT>the Agent shall use its commercially reasonable efforts, consistent with
its normal trading and sales practices and applicable law and regulations, to sell all of the Shares so designated by the Company in
accordance with such instruction. Each of the Company and the Agent acknowledges and agrees that (A) there can be no assurance that the
Agent will be successful in selling any Shares and (B) the Agent will not incur any liability or obligation to the Company if it fails
to sell Shares for any reason other than a failure to use its commercially reasonable efforts, consistent with its normal trading and
sales practices and applicable law and regulations, to sell such Shares as required by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company or the Agent, with respect to the sale of Shares made as sales agent on any Trading Day, may, upon notice to the other party
hereto by telephone (confirmed promptly by email, which confirmation will be promptly acknowledged by the receiving party), suspend the
offering of Shares with respect to which the Agent is acting as sales agent for any reason and at any time&#894; <U>provided</U>, <U>however</U>,
that such suspension shall not affect or impair the parties&#8217; respective obligations with respect to the Shares sold, or with respect
to Shares that the Company has agreed to sell, hereunder prior to the giving of such notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
gross sales price of any Shares sold pursuant to this Agreement by the Agent acting as sales agent of the Company shall be equal to,
in the discretion of the Agent but subject to the specific instructions of the Company, the market price prevailing at the time of sale
for the Shares sold by the Agent on the NYSE American or otherwise, at prices related to prevailing market prices or at negotiated prices.
The compensation payable to the Agent for sales of Shares with respect to which the Agent acts as sales agent shall be 3.0% of the gross
sales price for such Shares. The remaining proceeds, after further deduction for any transaction fees, transfer taxes or similar taxes
or fees imposed by any clearing firm, execution broker, Governmental Entity or self-regulatory organization in respect of such sales,
shall constitute the net proceeds to the Company for such sales (the &#8220;<U>Net Proceeds</U>&#8221;). The Agent shall notify the Company
as promptly as practicable if any deduction referenced in this Section 2(d) will be made. Notwithstanding the foregoing, in the event
the Company engages the Agent as sales agent for the sale of Shares that would constitute a &#8220;distribution&#8221; within the meaning
of Rule 100 of Regulation M under the 1934 Act, the Company and the Agent will agree to compensation for the Agent that is customary
for such sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
acting as sales agent hereunder, the Agent shall provide written confirmation to the Company following the close of trading on the NYSE
American on each Trading Day on which Shares are sold under this Agreement setting forth (i) the number of Shares sold on such day, (ii)
the aggregate gross sales proceeds of the Shares, (iii) the aggregate Net Proceeds to the Company and (iv) the aggregate compensation
payable by the Company to the Agent with respect to such sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
no circumstances shall the aggregate gross sales price or number, as the case may be, of Shares offered or sold pursuant to this Agreement,
or which are the subject of instructions to the Agent as sales agent pursuant to Section 2(b) hereof, exceed the aggregate gross sales
price or number, as the case may be, of Shares (i) referred to in the preamble paragraph of this Agreement, as reduced by prior sales
of Shares under this Agreement, (ii) available for sale under the Registration Statement or (iii) duly authorized from time to time to
be issued and sold under this Agreement by the Company or approved for listing on the NYSE American, and, in each case referred to in
clause (ii) and (iii), notified to the Agent in writing. In addition, under no circumstances shall any Shares with respect to which the
Agent acts as sales agent be offered or sold, or be the subject of instructions to the Agent as sales agent pursuant to Section 2(b)
hereof, at a price lower than the minimum price therefor duly authorized from time to time by the Company and notified to the Agent in
writing. The Agent shall have no responsibility for maintaining records with respect to Shares or maximum gross proceeds available for
sale under the Registration Statement or for determining the aggregate gross sales price, number or minimum price of Shares duly authorized
by the Company or approved for listing on the NYSE American.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the exemptive provisions set forth in Rule 101(c)(1) of Regulation M under the 1934 Act become satisfied with respect to the Company
or the Shares, the Company shall promptly notify the Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Settlement
for sales of Shares will occur at 10:00 a.m. (New York City time) on the second business day that is also a Trading Day following the
trade date on which such sales are made (or such earlier day as is industry practice for regular-way trading), unless another date shall
be agreed to in writing by the Company and the Agent (each such day, a &#8220;<U>Settlement Date</U>&#8221;). On each Settlement Date
for the sale of Shares through the Agent as sales agent, such Shares shall be delivered by the Company to the Agent in book-entry form
to the Agent&#8217;s account </FONT>at The Depository Trust Company against payment by the Agent of the Net Proceeds from the sale of
such Shares in same day funds delivered to an account designated by the Company. If the Company shall default on its obligation to deliver
Shares through the Agent as sales agent on any Settlement Date, the Company shall (i) indemnify and hold the Agent harmless against any
loss, claim or damage arising from or as a result of such default by the Company and (ii) pay the Agent any commission to which it would
otherwise be entitled absent such default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
any other provision of this Agreement, the Company shall not offer or sell, or instruct the Agent to offer or sell, any Shares through
the Agent as sales agent (and, by notice to the Agent given by telephone (confirmed promptly by email), and shall cancel any instructions
for any such offer or sale of any Shares prior to the commencement of the periods referenced below), and the Agent shall not be obligated
to make any such offer or sale of Shares, (i) during any period in which the Company is, or could be deemed to be, in possession of material
non-public information or (ii) except as provided in Section 2(j) hereof, at any time during the period commencing on the 10<SUP>th</SUP>
business day prior to the time that the Company issues a press release containing, or shall otherwise publicly announce, its earnings,
revenues or other operating results for a fiscal period or periods (each, an &#8220;<U>Earnings Announcement</U>&#8221;) through and
including the time that is 24 hours after the time that the Company files a Quarterly Report on Form 10-Q or an Annual Report on Form
10-K (a &#8220;<U>Filing Time</U>&#8221;) that includes consolidated financial statements as of and for the same fiscal period or periods,
as the case may be, covered by such Earnings Announcement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
clause (ii) of Section 2(i) hereof, if the Company wishes to offer or sell Shares to the Agent as sales agent at any time during the
period from and including an Earnings Announcement through and including the corresponding Filing Time, the Company shall first (i) prepare
and deliver to the Agent (with a copy to counsel for the Agent) a Current Report on Form 8-K that includes substantially the same financial
and related information (together with management&#8217;s discussion and analysis thereof) that was included in such Earnings Announcement
(other than any earnings projections and similar forward-looking data and officers&#8217; quotations) (each, an &#8220;<U>Earnings 8-K</U>&#8221;),
in form and substance reasonably satisfactory to the Agent, and, prior to its filing, obtain the written consent of the Agent to such
filing (which consent shall not be unreasonably withheld), (ii) provide the Agent with the officers&#8217; certificate, opinions and
letters of counsel and accountants&#8217; letter specified in Section 3(o), (p) and (q), respectively, hereof, (iii) afford the Agent
the opportunity to conduct a due diligence review in accordance with Section 3(t) hereof prior to filing such Earnings 8-K and (iv) file
such Earnings 8-K with the Commission. For purposes of clarity, the parties hereto agree that (A) the delivery of any officers&#8217;
certificate, opinion or letter of counsel or accountants&#8217; letter pursuant to this Section 2(j) shall not relieve the Company from
any of its obligations under this Agreement with respect to any Quarterly Report on Form 10-Q or Annual Report on Form 10-K, as the case
may be, including, without limitation, the obligation to deliver officers&#8217; certificates, opinions and letters of counsel and accountants&#8217;
letters as provided in Section 3(o), (p) and (q), respectively, hereof, and (B) this Section 2(j) shall in no way affect or limit the
operation of clause (i) of Section 2(i) hereof, which shall have independent application.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Agent shall not have any obligation to purchase Shares as principal, whether from the Company or otherwise, unless the Company and the
Agent agree as set forth below. Shares purchased from the Company by the Agent as principal shall be made in accordance with terms agreed
upon between the Agent and the Company as evidenced by a Terms Agreement. The Agent&#8217;s commitment to purchase Shares from the Company
as principal shall be deemed to have been made on the basis of the accuracy of the representations and warranties of the Company, and
performance by the Company of its covenants and other obligations, herein contained and shall be subject to the terms and conditions
herein set forth. At the time of each Terms Agreement, the Agent shall specify the requirements, if any, for the officers&#8217; certificate,
opinions and letters of counsel and accountants&#8217; letter pursuant to Section 3(o), (p) and (q), respectively, hereof. In the event
of a conflict between the terms of this Agreement and a Terms Agreement, the terms of such Terms Agreement shall control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Covenants</U>. The Company agrees with the Agent:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Compliance
with Securities Regulations and Commission Requests</I>. The Company, subject to Sections 3(b) and 3(c) hereof, will use its commercially
reasonable efforts to comply with the requirements of Rule 430B, and will promptly notify the Agent (i) when any post-effective amendment
to the Registration Statement or any new registration statement relating to the Shares shall become effective or any amendment or supplement
to the Prospectus shall have been filed (other than an amendment or supplement providing solely for the determination of the terms of
an offering of securities unless related to an offering of Shares, as to which the Company will only be </FONT>obligated to notify the
Agent), (ii) of the receipt of any comments from the Commission, (iii) of any request by the Commission for any amendment to the Registration
Statement or any amendment or supplement to the Prospectus, including any document incorporated by reference therein, or for additional
information, (iv) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any
post-effective amendment thereto or any notice of objection to the use of the Registration Statement or any post-effective amendment
thereto pursuant to Rule 401(g)(1) or of the issuance of any order preventing or suspending the use of any preliminary prospectus or
the Prospectus or any amendment or supplement thereto, or of the suspension of the qualification of any Shares for offering or sale in
any jurisdiction, or of the initiation or threatening of any proceedings for any of such purposes or of any examination pursuant to Section
8(d) or 8(e) of the 1933 Act concerning the Registration Statement and (v) if the Company becomes the subject of a proceeding under Section
8A of the 1933 Act in connection with any offering of Shares. In connection with a Terms Agreement, the Company will prepare and file
with the Commission, subject to Section 3(c) hereof, a pricing supplement with respect to the offer and sale of Shares covered by such
Terms Agreement. The Company will effect all filings required under Rule 424(b), in the manner and within the time period required by
Rule 424(b) (without reliance on Rule 424(b)(8)), and will take such steps as it deems necessary to ascertain promptly whether the form
of prospectus transmitted for filing under Rule 424(b) was received for filing by the Commission and, in the event that it was not, it
will promptly file such prospectus. The Company will make every reasonable effort to prevent the issuance of any stop, prevention or
suspension order and, if any such order is issued, to obtain the lifting thereof at the earliest possible moment. In the event of any
issuance of a notice of objection, by the Commission, the Company shall take all necessary action to permit offers and sales of Shares
by or through the Agent, including, without limitation, amending the Registration Statement or filing a new shelf registration statement
relating thereto. The Company shall pay the required Commission filing fees relating to the Shares prior to the time the initial Prospectus
Supplement is filed with the Commission or the time any subsequent Prospectus Supplement that increases the gross offering price or number
of Shares that may offered and sold under this Agreement from that referenced in the immediately preceding Prospectus Supplement filed
with the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Continued
Compliance with Securities Laws</I>. The Company will use its commercially reasonable efforts to comply with the 1933 Act, the 1933 Act
Regulations, the 1934 Act and the 1934 Act Regulations so as to permit the completion of sales of Shares as contemplated in this Agreement
and in the Registration Statement, the General Disclosure Package and the Prospectus. If any event shall occur or condition shall exist
as a result of which it is necessary, in the opinion of counsel for the Agent or counsel for the Company, to (i) amend the Registration
Statement in order that the Registration Statement will not include an untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary to make the statements therein not misleading, (ii) amend or supplement the General Disclosure
Package or the Prospectus in order that the General Disclosure Package or the Prospectus, as the case may be, will not include any untrue
statement of a material fact or omit to state a material fact necessary in order to make the statements therein not misleading in the
light of the circumstances existing at the time it is delivered to a purchaser or (iii) amend the Registration Statement or amend or
supplement the General Disclosure Package or the Prospectus, as the case may be, including, without limitation, the filing of any document
incorporated by reference therein, in order to comply with the requirements of the 1933 Act, the 1933 Act Regulations, the 1934 Act or
the 1934 Act Regulations, the Company will promptly (A) give the Agent written notice of such event or condition, (B) prepare any amendment
or supplement as may be necessary to correct such statement or omission or to comply with such requirements and, a reasonable amount
of time prior to any proposed filing or use, furnish the Agent with copies of any such amendment or supplement and will not file or use
any such amendment or supplement to which the Agent or counsel for the Agent shall reasonably object and (C) file with the Commission
any such amendment or supplement and use its commercially reasonable efforts to have any amendment to the Registration Statement declared
effective by the Commission as soon as practicable if the Company is no longer eligible to file a shelf registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Filing
or Use of Amendments and Supplements</I>. The Company will give the Agent written notice of its intention to file or use (i) any amendment
to the Registration Statement or any amendment or supplement to the General Disclosure Package or the Prospectus (other than an amendment
or supplement thereto relating solely to the offering of securities unless related to an offering of Shares), whether pursuant to the
1933 Act, the 1934 Act or otherwise, (ii) any new Prospectus Supplement that includes information in addition to the information referred
to in Section 3(n) hereof or (iii) a pricing supplement disclosing the offer and sale of Shares covered by a Terms Agreement, will furnish
the Agent with copies of any such document a reasonable amount of time prior to such </FONT>proposed filing or use, as the case may be,
and will not file or use any such document to which the Agent or counsel for the Agent shall reasonably object.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Delivery
of Registration Statements</I>. The Company has furnished or will deliver to the Agent and counsel for the Agent, without charge, signed
copies of the Registration Statement as originally filed and each amendment thereto (including exhibits filed therewith or incorporated
by reference therein and documents incorporated or deemed by the Company to be incorporated by reference therein) and signed copies of
all consents and certificates of experts<FONT STYLE="background-color: white">; <U>provided</U>, <U>however</U>, that the Company shall
not be required to furnish any document to the Agent or its counsel to the extent such document is available on EDGAR</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Delivery
of Prospectuses</I>. The Company will furnish to the Agent, without charge, upon execution of this Agreement and thereafter during the
period in which a prospectus is (or, but for the exception afforded by Rule 172 of the 1933 Act Regulations (&#8220;<U>Rule 172</U>&#8221;),
would be) required by the 1933 Act to be delivered in connection with any offer or sale of Shares, such number of copies of the Prospectus
(as amended or supplemented) as the Agent may reasonably request. The Company will also furnish, upon request of the Agent, copies of
the Prospectus (as amended or supplemented) to each exchange or market on which sales of Shares were made as may be required by the rules
and regulations of such exchange or market. The Prospectus and any amendments or supplements thereto furnished in accordance with this
Section 3(e) will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to
the extent permitted by Regulation S-T.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Reporting
Requirements</I>. The Company, during the period in which a prospectus is (or, but for the exception afforded by Rule 172, would be)
required by the 1933 Act to be delivered in connection with any offer or sale of Shares, will file all documents required to be filed
with the Commission pursuant to the 1934 Act within the time periods prescribed by, and meeting the requirements of, the 1934 Act and
the 1934 Act Regulations. Additionally, the Company shall report the use of the net proceeds from the sale of any Shares as may be required
under the 1933 Act and the 1933 Act Regulations, including, if applicable, Rule 463 of the 1933 Act Regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Blue
Sky Qualifications</I>. The Company will cooperate with the Agent to qualify the Shares for offering and sale under the applicable securities
laws of such states and non-U.S. jurisdictions as the Agent, may, from time to time, designate and to maintain such qualifications in
effect so long as required to complete the sale of the Shares contemplated by this Agreement&#894; <U>provided</U>, <U>however</U>, that
the Company shall not be obligated to file any general consent to service of process or to qualify as a foreign corporation or as a dealer
in securities in any jurisdiction in which it is not so qualified or to subject itself to taxation in respect of doing business in any
jurisdiction in which it is not otherwise so subject.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Earnings
Statement</I>. The Company will timely file such reports pursuant to the 1934 Act as are necessary in order to make generally available
to its securityholders as soon as practicable an earnings statement for the purposes of, and to provide to the Agent with the benefits
contemplated by, the last paragraph of Section 11(a) of the 1933 Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Use
of Proceeds</I>. The Company will use the net proceeds received by it from the sale of the Shares pursuant to this Agreement in the manner
specified in the Registration Statement, the General Disclosure Package and the Prospectus under &#8220;Use of Proceeds.&#8221;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Listing</I>.
The Company will use its reasonable best efforts to effect and maintain the listing of the Shares on, and satisfy the requirements of,
the NYSE American.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Notice
of Certain Actions</I>. <FONT STYLE="background-color: white">During the period beginning on the commencement of an offering of Shares
under this Agreement and ending on the applicable Settlement Date, t</FONT>he Company will not, without the prior written consent of
the Agent, unless it gives the Agent at least three business days&#8217; prior written notice, (i) directly or indirectly offer, pledge,
sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or
warrant to purchase or otherwise transfer or dispose of any shares of Common Stock or any securities convertible into or exercisable
or exchangeable for shares of Common Stock or file any registration statement under the 1933 Act with respect to any of the foregoing
or (ii) enter into any swap or any other agreement or transaction that transfers, in whole or in part, directly or indirectly, the economic
consequence of ownership of the Common Stock, whether any such swap, agreement or transaction described in clause (i) or (ii) above is
to be settled by delivery of Common Stock or such other securities, in cash or otherwise. The foregoing </FONT>sentence shall not apply
to (A) Shares to be sold hereunder, (B) any shares of Common Stock issued by the Company upon the exercise of an option or warrant or
the conversion of a security outstanding on the date hereof and referred to in the Registration Statement, the General Disclosure Package
and the Prospectus, (C) any shares of Common Stock issued or options to purchase Common Stock, granted pursuant to existing employee
benefit plans of the Company referred to in the Registration Statement, the General Disclosure Package and the Prospectus, (D) any shares
of Common Stock issued pursuant to any non-employee director stock plan or dividend reinvestment plan referred to in the Registration
Statement, the General Disclosure Package and the Prospectus or (E) <FONT STYLE="background-color: white">any shares of Common Stock,
or securities convertible into or exercisable for Common Stock, offered and sold in a privately negotiated transaction to vendors, customers,
strategic partners or potential strategic partners or other investors conducted in a manner so as not to be integrated with the offering
of Common Stock hereby and not to </FONT>constitute a distribution for purposes of Regulation M<FONT STYLE="background-color: white">,
provided that such shares of Common Stock and the shares of Common Stock underlying such securities upon such conversion or exercise,
in aggregate, do not exceed 5% of the Common Stock outstanding immediately prior to giving effect to such conversion or exercise</FONT>.
Upon receipt of any written notice contemplated above, the Agent may suspend its activity under this Agreement for such period of time
as deemed reasonably appropriate by the Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Issuer
Free Writing Prospectuses</I>. At all times during such period as the Prospectus is required by law to be delivered in connection with
sales of the Shares, the Company agrees that, unless it obtains the prior written consent of the Agent, it will not make any offer relating
to the Shares that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a &#8220;free writing prospectus,&#8221;
or a portion thereof, required to be filed by the Company with the Commission or retained by the Company under Rule 433. The Company
represents that it has treated or agrees that it will treat each such free writing prospectus consented to by the Agent as an &#8220;issuer
free writing prospectus,&#8221; as defined in Rule 433, and that it will comply with the applicable requirements of Rule 433 with respect
thereto, including timely filing with the Commission where required, legending and record keeping. If at any time following the issuance
of an Issuer Free Writing Prospectus any event shall occur or condition shall exist as a result of which such Issuer Free Writing Prospectus
conflicted or would conflict with the information contained in the Registration Statement, any preliminary prospectus or the Prospectus
or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order
to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will
promptly notify the Agent and will promptly amend or supplement, at its own expense, such Issuer Free Writing Prospectus to eliminate
or correct such conflict, untrue statement or omission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>No
Stabilization or Manipulation</I>. The Company agrees that neither it nor any affiliate of the Company will take, directly or indirectly,
any action which is designed, or would be expected, to cause or result in, or which constitutes, the stabilization or manipulation of
the price of any security of the Company to facilitate the sale or resale of any Shares or to result in a violation of Regulation M under
the 1934 Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Update
of Activity under this Agreement</I>. The Company shall disclose (i) in each Annual Report on Form 10-K or Quarterly Report on Form 10-Q
filed by the Company in respect of any fiscal quarterly period (which, in the case of an Annual Report on Form 10-K, would mean the last
quarterly period of the fiscal year) in which sales of Shares were made by or through the Agent under this Agreement (each date on which
any such document or amendment thereto is filed, a &#8220;<U>Company Periodic Report Date</U>&#8221;), or (ii) to the extent required
by applicable law and/or interpretations of the Commission, in one or more Prospectus Supplements for each such fiscal quarterly period,
the number of Shares sold by or through the Agent under this Agreement during such fiscal quarterly period, the net proceeds received
by the Company and the aggregate compensation paid by the Company to the Agent with respect to such sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Delivery
of Future Officers&#8217; Certificates</I>. Upon commencement of the offering of Shares under this Agreement, (A) each time Shares are
delivered to the Agent as principal on a Settlement Date, (B) promptly after each (i) date on which the Registration Statement shall
be amended or a new registration statement relating to the Shares shall become effective or the Prospectus shall be amended or supplemented
(other than (1) in connection with the filing of a Prospectus Supplement that contains solely the information referred to in Section
3(n) hereof, or (2) in connection with the filing of any Current Report on Form 8-K (other than an Earnings 8-K and any other Current
Report on Form 8-K which contains financial statements, supporting schedules or other financial data, including any Current Report on
Form 8&#45;K under Item 2.02 of such form, that is considered &#8220;filed&#8221; under the 1934 Act) (each such date, a &#8220;<U>Registration
Statement Amendment Date</U>&#8221;), (ii) date on which an Earnings 8-K shall be </FONT>filed with the Commission as contemplated by
Section 2(j) hereof (a &#8220;<U>Company Earnings Report Date</U>&#8221;) and (iii) Company Periodic Report Date, and (C) promptly after
each reasonable request by the Agent (each date of any such request by the Agent, a &#8220;<U>Request Date</U>&#8221;), the Company will
furnish or cause to be furnished to the Agent an officers&#8217; certificate, dated such Settlement Date, such Registration Statement
Amendment Date, such Company Earnings Report Date, such Company Periodic Report Date or such Request Date, as the case may be, in form
and substance reasonably satisfactory to the Agent, to the effect that the statements contained in the officers&#8217; certificate referred
to in Section 5(f) hereof that was last furnished to the Agent are true and correct as of the date of such certificate as though made
at and as of the date of such certificate (except that such statements shall be deemed to relate to the Registration Statement, the General
Disclosure Package and the Prospectus as amended and supplemented at the date of such certificate) or, in lieu of such certificate, a
certificate of the same tenor as the certificate referred to in Section 5(f) hereof but modified as necessary to relate to the Registration
Statement, the General Disclosure Package and the Prospectus as amended and supplemented at the date of such certificate. As used in
this Section 3(o), to the extent there shall be a sale of Shares on or following any Registration Statement Amendment Date, Company Earnings
Report Date, Company Periodic Report Date or Request Date, &#8220;promptly&#8221; shall be deemed to be at or prior to the Applicable
Time for such sale. <FONT STYLE="background-color: white">The requirement to provide a certificate under this paragraph shall be waived
for any </FONT>Registration Statement Amendment Date, Company Earnings Report Date, or Company Periodic Report Date <FONT STYLE="background-color: white">on
which there is not an offering of Shares under this Agreement, provided that, if the Company subsequently decides to sell Shares following
such </FONT>Registration Statement Amendment Date, Company Earnings Report Date, or Company Periodic Report Date when the Company relied
upon waiver as described in this sentence, the Company shall, prior to Company&#8217;s instruction to the Agent to sell Shares under
this Agreement, deliver the officers&#8217; certificate required hereunder<FONT STYLE="background-color: white">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Delivery
of Future Opinions and Letters of Counsel</I>. Upon commencement of the offering of Shares under this Agreement, (A) each time Shares
are delivered to the Agent as principal on a Settlement Date and (B) promptly after each Registration Statement Amendment Date, Company
Earnings Report Date, Company Periodic Report Date or Request Date, the Company will furnish or cause to be furnished to the Agent the
written opinions and letters of each of New York counsel, Israeli counsel and intellectual property counsel for the Company (who shall
be reasonably acceptable to the Agent) and counsel for the Agent, dated such Settlement Date, such Registration Statement Amendment Date,
such Company Earnings Report Date, such Company Periodic Report Date or such Request Date, as the case may be, in form and substance
reasonably satisfactory to the Agent, of the same tenor as the respective opinions and letters referred to in Sections 5(b) and 5(c),
as applicable, hereof but modified as necessary to relate to the Registration Statement, the General Disclosure Package and the Prospectus
as amended and supplemented to the date of such opinion and letter in lieu of any such opinion and letter, counsel last furnishing such
opinion and letter to the Agent shall furnish the Agent with a letter substantially to the effect that the Agent may rely on such counsel&#8217;s
last opinion and letter to the same extent as though each were dated the date of such letter authorizing reliance (except that statements
in such last opinion and letter shall be deemed to relate to the Registration Statement, the General Disclosure Package and the Prospectus
as amended and supplemented to the date of such letter authorizing reliance). As used in this Section 3(p), to the extent there shall
be a sale of Shares on or following any Registration Statement Amendment Date, Company Earnings Report Date, Company Periodic Report
Date or Request Date, &#8220;promptly&#8221; shall be deemed to be at or prior to the Applicable Time for such sale. <FONT STYLE="background-color: white">The
requirement to provide the opinions and letters under this paragraph shall be waived for any </FONT>Registration Statement Amendment
Date, Company Earnings Report Date, or Company Periodic Report Date <FONT STYLE="background-color: white">on which there is not an offering
of Shares under this Agreement, provided that, if the Company subsequently decides to sell Shares following such </FONT>Registration
Statement Amendment Date, Company Earnings Report Date, or Company Periodic Report Date when the Company relied upon waiver as described
in this sentence, the Company shall, prior to Company&#8217;s instruction to the Agent to sell Shares under this Agreement, deliver the
opinions and letters required hereunder<FONT STYLE="background-color: white">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Delivery
of Future Accountants&#8217; Letters</I>. Upon commencement of the offering of Shares under this Agreement, (A) each time Shares are
delivered to the Agent as principal on a Settlement Date and (B) promptly after each Registration Statement Amendment Date, Company Earnings
Report Date, Company Periodic Report Date or Request Date, the Company will cause its independent accountants to furnish to the Agent
a letter, dated such Settlement Date, such Registration Statement Amendment Date, such Company Earnings Report Date, such Company Periodic
Report Date or such Request Date, as the case may be, in form and substance reasonably satisfactory to the Agent, of the same tenor as
the letter referred to in Section 5(d) hereof but modified as necessary to relate to the Registration Statement, the General Disclosure
Package and the Prospectus as amended and </FONT>supplemented to the date of such letter. As used in this paragraph, to the extent there
shall be a sale of Shares on or following any Registration Statement Amendment Date, Company Earnings Report Date, Company Periodic Report
Date or Request Date, &#8220;promptly&#8221; shall be deemed to be at or prior to the Applicable Time for such sale. <FONT STYLE="background-color: white">The
requirement to provide the letter under this paragraph shall be waived for any </FONT>Registration Statement Amendment Date, Company
Earnings Report Date, or Company Periodic Report Date <FONT STYLE="background-color: white">on which there is not an offering of Shares
under this Agreement, provided that, if the Company subsequently decides to sell Shares following such </FONT>Registration Statement
Amendment Date, Company Earnings Report Date, or Company Periodic Report Date when the Company relied upon waiver as described in this
sentence, the Company shall, prior to Company&#8217;s instruction to the Agent to sell Shares under this Agreement, deliver the letter
required hereunder<FONT STYLE="background-color: white">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Trading
in the Common Stock</I>. The Company consents to the Agent trading in the Company&#8217;s Common Stock for its own account and for the
account of its clients at the same time as sales of Shares occur pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Non-Consummation
Offer</I>. If, to the knowledge of the Company, any filing required by Rule 424 in connection with an offering of Shares shall not have
been made or the representations and warranties of the Company contained in this Agreement shall not be true and correct on the applicable
Settlement Date, the Company will offer to any person who has agreed to purchase Shares from or through the Agent the right to refuse
to purchase and pay for such Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Due
Diligence Review</I>. (i) Upon commencement of the offering of Shares under this Agreement, (ii) prior to each time Shares are delivered
to the Agent as principal on a Settlement Date, (iii) promptly after each Registration Statement Amendment Date, Company Earnings Report
Date, Company Periodic Report Date or Request Date and (iv) at any time reasonably requested by the Agent, the Company will cooperate
with any due diligence review by the Agent or counsel for the Agent, fully and in a timely manner, in connection with offers and sales
of Shares from time to time, including, without limitation, and upon reasonable notice, providing information and making available documents
and appropriate corporate officers, during regular business hours and at the Company&#8217;s principal offices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(u)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Renewal
Deadline</I>. If, immediately prior to the third anniversary of the initial effective date of the Registration Statement (the &#8220;<U>Renewal
Deadline</U>&#8221;), this Agreement is still in effect or any Shares purchased by the Agent as principal remain unsold, the Company
will, prior to the Renewal Deadline, (i) promptly notify the Agent and (ii) promptly file, if it is eligible to do so, an automatic shelf
registration statement relating to the Shares, in a form and substance satisfactory to the Agent. If, at the time the Company intends
to file such an automatic shelf registration statement, it is not eligible to do so, the Company will, prior to the Renewal Deadline,
(i) promptly notify the Agent, (ii) promptly file a new shelf registration statement on the proper form relating to the Shares, in a
form and substance satisfactory to the Agent, (iii) use its commercially reasonable efforts to cause such new shelf registration statement
to be declared effective within 90 days after the Renewal Deadline and (iv) promptly notify the Agent of such effectiveness. The Company
will take all other action necessary or appropriate to permit the offering and sale of the Shares to continue as contemplated in the
expired Registration Statement. References herein to the &#8220;Registration Statement&#8221; shall include such new automatic shelf
registration statement or such new shelf registration statement, as the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Ceasing
Eligibility For Use of Shelf Registration Statement Form</I>. If, at any time, during the term of this Agreement or otherwise when Shares
purchased by the Agent as principal remain unsold, the Company receives a notice from the Commission pursuant to Rule 401(g)(1) or otherwise
ceases to be eligible to use the shelf registration statement form, the Company will (i) promptly notify the Agent, (ii) promptly file
a new registration statement or post-effective amendment on the proper form relating to such Shares, in form and substance satisfactory
to the Agent, (iii) use its commercially reasonable efforts to cause such new registration statement or post-effective amendment to be
declared effective as soon as practicable and (iv) promptly notify the Agent of such effectiveness. The Company will take all other action
necessary or appropriate to permit the offering and sale of the Shares to continue as contemplated in the Registration Statement that
was the subject of the Rule 401(g)(1) notice or for which the Company has otherwise become ineligible. References herein to the &#8220;Registration
Statement&#8221; shall include such new registration statement or post-effective amendment, as the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Payment of Expenses</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Expenses</I>.
The Company will pay or cause to be paid all expenses incident to the performance of the Company&#8217;s obligations under this Agreement,
including (i) the preparation, printing and filing of the Registration Statement (including financial statements and exhibits) as originally
filed and each amendment or supplement thereto, (ii) the preparation, printing and delivery to the Agent of copies of any preliminary
prospectus, any Issuer Free Writing Prospectus and the Prospectus and any amendments or supplements thereto and any costs associated
with electronic delivery of any of the foregoing by the Agent to investors, (iii) the preparation, issuance and delivery of the certificates
for the Shares, including any stock or other transfer taxes and any stamp or other duties payable upon the sale, issuance or delivery
by the Company of the Shares to the Agent, (iv) the fees and disbursements of the Company&#8217;s counsels, accountants and other advisors,
(v) the qualification of the Shares under securities laws in accordance with the provisions of Section 3(g) hereof, (vi) the fees and
expenses of any transfer agent or registrar for the Shares, (vii) the costs and expenses of the Company relating to investor presentations
on any &#8220;road show&#8221; undertaken in connection with the marketing of the Shares, (viii) the filing fees incident to, and the
reasonable fees and disbursements of counsel for the Agent in connection with, the review by FINRA of the terms of sales of Shares in
an amount not to exceed $10,000, (ix) the fees and expenses incurred in connection with the listing of the Shares on the NYSE American,
(x) the reasonable documented out-of-pocket expenses of the Agent, including the reasonable fees, disbursements and expenses of counsel
for the Agent in an amount not to exceed $50,000 in connection with this Agreement and the Registration Statement and ongoing services
in connection with the transactions contemplated hereunder, (xi) the costs and expenses (including, without limitation, any damages or
other amounts payable in connection with legal or contractual liability) associated with the reforming of any contracts for the sale
of Shares caused by a breach of the representation contained in the second sentence of Section 1(a)(ii) hereof, and (xii) all other costs
and expenses incident to the performance by the Company of its obligations hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conditions of Agent&#8217;s Obligations</U>. The obligations of
the Agent hereunder are subject to the accuracy of the representations and warranties of the Company contained herein or in certificates
of any officer of the Company or any of its subsidiaries delivered pursuant to the provisions hereof at each Representation Date, to
the performance by the Company of its covenants and other obligations hereunder, and to the following further conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Effectiveness
of Registration Statement and Filing of Prospectus</I>. The Company shall have filed the Registration Statement with the Commission not
earlier than three years prior to the date hereof and the Registration Statement was declared effective by the Commission on April 12,
2019. The Company shall have filed with the Commission the Prospectus on or prior to the date of this Agreement and any subsequent Base
Prospectus or Prospectus Supplement prior to any Applicable Time and related Settlement Date, as applicable, in each case in the manner
and within the time period required by Rule 424(b), and each Issuer Free Writing Prospectus, if any, in the manner and within the time
period required by Rule 433. No stop order suspending the effectiveness of the Registration Statement or any post-effective amendment
thereto has been issued under the 1933 Act, no notice of objection of the Commission to the use of the Registration Statement or any
post-effective amendment thereto pursuant to Rule 401(g)(1) has been received by the Company, no order preventing or suspending the use
of any preliminary prospectus or the Prospectus or any amendment or supplement thereto has been issued and no proceedings for any of
those purposes have been instituted or are pending or, to the Company&#8217;s knowledge, contemplated. The Company shall have complied
with any and all requests for additional information on the part of the Commission to the reasonable satisfaction of the Agent. The Company
shall have paid the required Commission filing fees relating to the Shares as specified in Section 3(a) hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Opinion
of Counsel for the Agent</I>. On the date of this Agreement, the Agent shall have received the favorable written opinion or opinions
of Ellenoff Grossman &amp; Schole LLP, counsel for the Agent, dated such date, with respect to such matters as the Agent may reasonably
request. In giving such opinion or opinions, such counsel may rely, as to all matters governed by the laws of jurisdictions other than
the laws of the State of New York, the General Corporation Law of the State of Delaware and the federal securities laws of the United
States, upon the opinions of counsel satisfactory to the Agent. Such counsel may also state that, insofar as such opinion involves factual
matters, they have relied, to the extent they deem proper, upon certificates of officers and other representatives of the Company and
its subsidiaries and certificates of public officials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Opinions
of Counsel for the Company</I>. On the date of this Agreement, the Agent shall have received the favorable written opinion or opinions
of (i) Mayer Brown LLP, New York counsel for the Company, dated such date, to the effect set forth in <U>Exhibit A</U> hereto and to
such further effect as the Agent may reasonably request, (ii) Horn &amp; Co. Law Offices, Israeli counsel for the Company, dated such
date, to the effect set forth in <U>Exhibit B</U> hereto and to such further effect as the Agent may reasonably request and (iii) Ehrlich
 &amp; Fenster, special intellectual property counsel for the Company, dated such date, to the effect set forth in <U>Exhibit C</U> hereto
and to such further effect as the Agent may reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Accountants&#8217;
Letter</I>. On the date of this Agreement, the Agent shall have received a letter from Kesselman &amp; Kesselman, a member of PricewaterhouseCoopers
International Limited, dated such date, in form and substance satisfactory to the Agent, containing statements and information of the
type ordinarily included in accountants&#8217; &#8220;comfort letters&#8221; to underwriters with respect to the financial statements
and other financial information included in the Registration Statement, the General Disclosure Package and the Prospectus or any amendment
or supplement thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Officer&#8217;s
Certificate on Size of ATM Program</I>. On the date of this Agreement, the Company shall have furnished to the Agent a certificate of
an executive officer of the Company, dated such date, in a form satisfactory to the Agent, stating the minimum gross sales price per
share for sales of Shares pursuant to this Agreement and the maximum number of Shares that may be issued and sold pursuant to this Agreement
or, alternatively, the maximum gross proceeds from such sales, as duly authorized by the Company&#8217;s board of directors or a duly
authorized committee thereof, and specify the number of Shares that have been approved for listing, subject to official notice of issuance,
on the NYSE American.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Officers&#8217;
Certificate for the Company</I>. On the date of this Agreement, there shall not have been, since the date of the latest audited financial
statements included in the Registration Statement, the General Disclosure Package and the Prospectus or since the respective dates as
of which information is given in the Registration Statement, the General Disclosure Package and the Prospectus, any Material Adverse
Change, and the Agent shall have received a certificate of the Chief Executive Officer or President of the Company and of the Chief Financial
Officer or Chief Accounting Officer of the Company, dated such date, to the effect that (A) there has been no such Material Adverse Change,
(B) the representations and warranties of the Company in this Agreement are true and correct with the same force and effect as though
expressly made on and as of such date, (C) the Company has complied with all agreements and satisfied all conditions on its part to be
performed or satisfied on or prior to such date and (D) no stop order suspending the effectiveness of the Registration Statement or any
post-effective amendment thereto has been issued under the 1933 Act, no notice of objection of the Commission to the use of the Registration
Statement or any post-effective amendment thereto pursuant to Rule 401(g)(1) has been received by the Company, no order preventing or
suspending the use of any preliminary prospectus or the Prospectus or any amendment or supplement thereto has been issued and no proceedings
for any of those purposes have been instituted or are pending or, to their knowledge, contemplated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Listing</I>.
The Shares shall have been approved for listing, subject to official notice of issuance, on the NYSE American.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Additional
Documents</I>. On the date of this Agreement, counsel for the Agent shall have been furnished with such documents and opinions as they
may require for the purpose of enabling them to render the opinions or make the statements requested by the Agent, or in order to evidence
the accuracy of any of the representations or warranties, or the fulfillment of any of the covenants, obligations or conditions, contained
herein&#894; and all proceedings taken by the Company in connection with the issuance and sale of the Shares as contemplated herein shall
be satisfactory in form and substance to the Agent and counsel for the Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>FINRA.
</I>FINRA shall not have raised any objection with respect to the fairness and reasonableness of the terms and arrangements under this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Termination
of this Agreement</I>. If any condition specified in this Section 5 shall not have been fulfilled when and as required to be fulfilled,
this Agreement may be terminated by the Agent by notice to the Company at any time, and any such termination shall be without liability
of any party to any other party except the </FONT>provisions of Sections 1, 3(h), 4, 6, 7, 8, 10, 12, 13, 14, 15 and 16 hereof shall
remain in full force and effect notwithstanding such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.9pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.9pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.9pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Indemnification
of the Agent</I>. The Company agrees to indemnify and hold harmless the Agent, its affiliates (as such term is defined in Rule 501(b)
of the 1933 Act Regulations (each, an &#8220;<U>Affiliate</U>&#8221;)), selling agents, officers, directors and each person, if any,
who controls the Agent within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">against
any and all loss, liability, claim, damage and expense whatsoever, as incurred, arising out of any untrue statement or alleged untrue
statement of a material fact contained in the Registration Statement (or any amendment thereto), including any information deemed to
be a part thereof pursuant to Rule 430B, or the omission or alleged omission therefrom of a material fact required to be stated therein
or necessary to make the statements therein not misleading or arising out of any untrue statement or alleged untrue statement of a material
fact included (A) in any preliminary prospectus, any Issuer Free Writing Prospectus, the General Disclosure Package or the Prospectus
(or any amendment or supplement thereto) or (B) in any materials or information provided to investors by, or with the approval of, the
Company in connection with the marketing of any offering of Shares (&#8220;<U>Marketing Materials</U>&#8221;), including any roadshow
or investor presentations made to investors by the Company (whether in person or electronically), or the omission or alleged omission
in any preliminary prospectus, any Issuer Free Writing Prospectus, the General Disclosure Package or the Prospectus (or any amendment
or supplement thereto) or in any Marketing Materials of a material fact necessary in order to make the statements therein, in the light
of the circumstances under which they were made, not misleading&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">against
any and all loss, liability, claim, damage and expense whatsoever, as incurred, to the extent of the aggregate amount paid in settlement
of any litigation, or any investigation or proceeding by any Governmental Entity, commenced or threatened, or of any claim whatsoever
based upon any such untrue statement or omission, or any such alleged untrue statement or omission&#894; <U>provided</U> that (subject
to Section 6(d) below) any such settlement is effected with the written consent of the Company&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">against
any and all expense whatsoever, as incurred (including the fees and disbursements of counsel chosen by the Agent), reasonably incurred
in investigating, preparing or defending against any litigation, or any investigation or proceeding by any Governmental Entity, commenced
or threatened, or any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission,
to the extent that any such expense is not paid under (i) or (ii) above&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>provided</U>,
<U>however</U>, that this indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising
out of any untrue statement or omission or alleged untrue statement or omission made in the Registration Statement (or any amendment
thereto), including any information deemed to be a part thereof pursuant to Rule 430B, or in the General Disclosure Package or the Prospectus
(or any amendment or supplement thereto), in each case in reliance upon and in conformity with information furnished to the Company by
the Agent in writing expressly for use therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Indemnification
of Company, Directors and Officers</I>. The Agent agrees to indemnify and hold harmless the Company, its directors, each of its officers
who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of Section 15 of the 1933
Act or Section 20 of the 1934 Act against loss, liability, claim, damage and expense described in the indemnity contained in Section
6(a) hereof, as incurred, but only with respect to untrue statements or omissions, or alleged untrue statements or omissions, made in
the Registration Statement (or any amendment thereto), including any information deemed to be a part thereof pursuant to Rule 430B, or
in the General Disclosure Package or the Prospectus (or any amendment or supplement thereto), in reliance upon and in conformity with
the information furnished to the Company by the Agent in writing expressly for use therein; <U>provided</U>, <U>however</U>, that in
no case shall the Agent be responsible for any amount in excess of the total commissions or underwriting discounts received by the Agent
in connection with Shares placed or underwritten by it pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Actions
against Parties&#894; Notification</I>. Each indemnified party shall give notice as promptly as reasonably practicable to each indemnifying
party of any action commenced against it in respect of which indemnity </FONT>may be sought hereunder, but failure to so notify an indemnifying
party shall not relieve such indemnifying party from any liability hereunder to the extent it is not materially prejudiced as a result
thereof and in any event shall not relieve it from any liability which it may have otherwise than on account of this indemnity agreement.
In the case of parties indemnified pursuant to Section 6(a) hereof, counsel for the indemnified parties shall be selected by the Agent,
and, in the case of parties indemnified pursuant to Section 6(b) hereof, counsel for the indemnified parties shall be selected by the
Company. An indemnifying party may participate at its own expense in the defense of any such action&#894; <U>provided</U>, <U>however</U>,
that counsel for the indemnifying party shall not (except with the prior written consent of the indemnified party) also be counsel for
the indemnified party. In no event shall the indemnifying parties be liable for fees and expenses of more than one counsel (in addition
to any local counsel) separate from their own counsel for all indemnified parties in connection with any one action or separate but similar
or related actions in the same jurisdiction arising out of the same general allegations or circumstances. No indemnifying party shall,
without the prior written consent of the indemnified parties, settle or compromise or consent to the entry of any judgment with respect
to any litigation, or any investigation or proceeding by any Governmental Entity, commenced or threatened, or any claim whatsoever in
respect of which indemnification or contribution could be sought under this Section 6 or Section 7 hereof (whether or not the indemnified
parties are actual or potential parties thereto), unless such settlement, compromise or consent (i) includes an unconditional release
of each indemnified party from all liability arising out of such litigation, investigation, proceeding or claim, and (ii) does not include
a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Contribution</U>. If the indemnification provided for in Section
6 hereof is for any reason unavailable or insufficient to hold harmless an indemnified party in respect of any losses, liabilities, claims,
damages or expenses referred to therein, then each indemnifying party shall contribute to the aggregate amount of such losses, liabilities,
claims, damages and expenses incurred by such indemnified party, as incurred, (i) in such proportion as is appropriate to reflect the
relative benefits received by the Company, on the one hand, and the Agent, on the other hand, from the applicable offering of Shares
or (ii) if the allocation provided by clause (i) is not permitted by applicable law, in such proportion as is appropriate to reflect
not only the relative benefits referred to in clause (i) above but also the relative fault of the Company, on the one hand, and the Agent,
on the other hand, in connection with the statements or omissions which resulted in such losses, liabilities, claims, damages or expenses,
as well as any other relevant equitable considerations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
relative benefits received by the Company, on the one hand, and the Agent, on the other hand, in connection with the applicable offering
of Shares shall be deemed to be in the same proportion as the total net proceeds from such offering (before deducting expenses) received
by the Company, on the one hand, bear to the total commissions or underwriting discounts received by the Agent, on the other hand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
relative fault of the Company, on the one hand, and the Agent, on the other hand, shall be determined by reference to, among other things,
whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates
to information supplied by the Company or by the Agent and the parties&#8217; relative intent, knowledge, access to information and opportunity
to correct or prevent such statement or omission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and the Agent agree that it would not be just and equitable if contribution pursuant to this Section 7 were determined by pro
rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to above in
this Section 7. The aggregate amount of losses, liabilities, claims, damages and expenses incurred by an indemnified party and referred
to above in this Section 7 shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in investigating,
preparing or defending against any litigation, or any investigation or proceeding by any Governmental Entity, commenced or threatened,
or any claim whatsoever based upon any such untrue or alleged untrue statement or omission or alleged omission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the provisions of this Section 7, the Agent shall not be required to contribute any amount in excess of the total commissions or underwriting
discounts received by the Agent in connection with Shares placed or underwritten by it for sale pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the 1933 Act) shall be entitled to contribution
from any person who was not guilty of such fraudulent misrepresentation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this Section 7, each person, if any, who controls the Agent within the meaning of Section 15 of the 1933 Act or Section 20
of the 1934 Act and the Agent&#8217;s Affiliates, selling agents, officers and directors shall have the same rights to contribution as
the Agent and each director of the Company, each officer of the Company who signed the Registration Statement, and each person, if any,
who controls the Company within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act shall have the same rights to
contribution as the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations, Warranties and Agreements to Survive</U>.
All representations, warranties and agreements contained in this Agreement or in certificates of officers of the Company or any of its
subsidiaries submitted pursuant hereto, shall remain operative and in full force and effect regardless of (i) any investigation made
by or on behalf of the Agent or its Affiliates, selling agents, officers, directors or any person controlling the Agent or the Company
or its officers, or any person controlling the Company and (ii) delivery of and payment for the Shares. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement may be terminated for any reason, at any time, by either the Company or the Agent, upon the giving of 3 days prior written
notice to the other party hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Agent may terminate a Terms Agreement to which it is a party, at any time at or prior to the Settlement Date, (i) if there has been,
in such judgment of the Agent, since the time of execution of such Terms Agreement or since the respective dates as of which information
is given in the Registration Statement, the General Disclosure Package or the Prospectus, any Material Adverse Change, or (ii) if there
has occurred any material adverse change in the financial markets in the United States or the international financial markets, any outbreak
of hostilities or escalation thereof or other calamity or crisis or any change or development involving a prospective change in national
or international political, financial or economic conditions, in each case the effect of which is such as to make it, in the judgment
of such Agent, impracticable or inadvisable to proceed with the completion of the offering of Shares contemplated by such Terms Agreement
or to enforce contracts for the sale of such Shares, or (iii) if trading in any securities of the Company has been suspended or materially
limited by the Commission or the NYSE American, or (iv) if trading generally on the NYSE, the NYSE American or Nasdaq has been suspended
or materially limited, or minimum or maximum prices for trading have been fixed, or maximum ranges for prices have been required, by
any of said exchanges or by order of the Commission, FINRA or any other Governmental Entity, or (v) if a material disruption has occurred
in commercial banking or securities settlement or clearance services in the United States or with respect to the systems of Clearstream
Banking, soci&eacute;t&eacute; anonyme, or Euroclear Bank, SA/NV, in Europe, or (vi) if a banking moratorium has been declared by either
Federal or New York authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Reserved]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of any termination under this Section 9, no party will have any liability to the other party hereto, except that (i) the Agent
shall be entitled to any commissions earned in accordance with Section 2(b) hereof, (ii) if at the time of termination (a) the Agent
shall own any Shares purchased by it as principal or (b) an offer to purchase any Shares has been accepted by the Company but the Settlement
Date has not occurred, the covenants set forth in Section 3 hereof shall remain in effect until such Shares are resold or so delivered,
as the case may be, and (iii) the covenant set forth in Section 3(h) hereof, the provisions of Section 4 hereof, the indemnity and contribution
agreements set forth in Sections 6 and 7 hereof, and the provisions of Sections 1, 8, 10, 12, 13, 14, 15 and 16 hereof shall remain in
effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>. All notices and other communications hereunder shall be
in writing and shall be deemed to have been duly given if mailed or transmitted by any standard form of telecommunication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices
to the Agent shall be directed to: H.C. Wainwright &amp; Co., LLC, 430 Park Avenue, New York, New York 10022, Attention: Chief Executive
Officer (email: notices@hcwco.com), with a copy to Ellenoff Grossman &amp; Schole LLP, 1345 Avenue of the Americas, New York, New York
10105, Attention: John Hart (email: jhart@egsllp.com).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices
to the Company shall be directed to it Protalix BioTherapeutics, Inc., 2 Snunit Street, Science Park P.O.B. 455, Carmiel 20100, Israel,
Attention: Dror Bashan (email: dror.bashan@protalix.com), with a copy to Mayer Brown LLP, 1221 Avenue of the Americas, New York, New
York 10020, Attention: Anna Pinedo </FONT>(email: APinedo@mayerbrown.com).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No Advisory or Fiduciary Relationship</U>. The Company acknowledges
and agrees that (a) each purchase and sale of Shares pursuant to this Agreement, including the determination of the respective initial
public offering prices of Shares, if any, and any related discounts and commissions, is an arm&#8217;s-length commercial transaction
between the Company, on the one hand, and the Agent, on the other hand, and does not constitute a recommendation, investment advice,
or solicitation of any action by the Agent or the Underwriters, (b) the Agent has not assumed and will not assume any advisory or fiduciary
responsibility in favor of the Company or any of its subsidiaries or other affiliates with respect to any offering of Shares or the process
leading thereto (irrespective of whether the Agent has advised or is currently advising the Company or any of its subsidiaries or other
affiliates on other matters) or any other obligation to the Company except the obligations expressly set forth in this Agreement, (c)
the Agent, and its affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Company,
and (d) the Agent has not provided any legal, accounting, financial, regulatory, investment or tax advice to the Company or any other
person or entity with respect to any offering of Shares and the Company has consulted its own respective legal, accounting, financial,
regulatory and tax advisors to the extent it deemed appropriate, and (f) none of the activities of the Agent or the Underwriters in connection
with the transactions contemplated herein constitutes a recommendation, investment advice or solicitation of any action by the Agent
or the Underwriters with respect to any entity or natural person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Recognition of the U.S. Special Resolution Regimes</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that the Agent that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer
from the Agent of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as
the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were
governed by the laws of the United States or a state of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that the Agent that is a Covered Entity or a BHC Act Affiliate of the Agent becomes subject to a proceeding under a U.S. Special
Resolution Regime, Default Rights under this Agreement that may be exercised against the Agent are permitted to be exercised to no greater
extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws
of the United States or a state of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this Section 12, a &#8220;<U>BHC Act Affiliate</U>&#8221; has the meaning assigned to the term &#8220;<U>affiliate</U>&#8221;
in, and shall be interpreted in accordance with, 12 U.S.C. &sect; 1841(k). &#8220;<U>Covered Entity</U>&#8221; means any of the following:
(i) a &#8220;covered entity&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 252.82(b)&#894; (ii)
a &#8220;covered bank&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 47.3(b)&#894; or (iii)
a &#8220;covered FSI&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 382.2(b). &#8220;<U>Default
Right</U>&#8221; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &sect;&sect; 252.81,
47.2 or 382.1, as applicable. &#8220;<U>U.S. Special Resolution Regime</U>&#8221; means each of (i) the Federal Deposit Insurance Act
and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the
regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Parties</U>. This Agreement shall each inure to the benefit of and be binding
upon the Agent and the Company and their respective successors. Nothing expressed or mentioned in this Agreement is intended or shall
be construed to give any person, firm or corporation, other than the Agent, its Affiliates and selling agents, the Company and their
respective successors and the controlling persons and officers and directors referred to in Sections 6 and 7 and their heirs and legal
representatives, any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision herein contained.
This Agreement and all conditions and provisions hereof are intended to be for the sole and exclusive benefit of the Agent, its Affiliates
and selling agents, the Company and their respective successors, and said controlling persons and officers and directors and their heirs
and legal representatives, and for the benefit of no other person, firm or corporation. No purchaser of Shares shall be deemed to be
a successor by reason merely of such purchase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Trial by Jury</U>. Each of the Company (on its behalf and, to the extent
permitted by applicable law, on behalf of its stockholders and affiliates) and the Agent hereby irrevocably waives, to the fullest </FONT>extent
permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement
or the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>GOVERNING LAW</U>. THIS AGREEMENT AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING
UNDER OR RELATED TO THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF, THE STATE OF NEW YORK WITHOUT
REGARD TO ITS CHOICE OF LAW PROVISIONS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Consent to Jurisdiction&#894; Waiver of Immunity</U>. Each of the Company
and the Agent agrees that any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated
hereby (&#8220;<U>Related Proceedings</U>&#8221;) shall be instituted in (i) the federal courts of the United States of America located
in the City and County of New York, Borough of Manhattan or (ii) the courts of the State of New York located in the City and County of
New York, Borough of Manhattan (collectively, the &#8220;<U>Specified Courts</U>&#8221;), and each party irrevocably submits to the exclusive
jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any Specified Court, as to which such jurisdiction
is non-exclusive) of the Specified Courts in any such suit, action or proceeding. Service of any process, summons, notice or document
by mail to such party&#8217;s address set forth in Section 10 hereof shall be effective service of process upon such party for any suit,
action or other proceeding brought in any Specified Court. Each of the Company and the Agent irrevocably and unconditionally waives any
objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally
waives and agrees not to plead or claim in any Specified Court that any such suit, action or other proceeding brought in any Specified
Court has been brought in an inconvenient forum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>TIME</U>. TIME SHALL BE OF THE ESSENCE OF THIS AGREEMENT. EXCEPT AS OTHERWISE
SET FORTH HEREIN, SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U>. This Agreement may be executed in any number of counterparts,
each of which shall be deemed to be an original, but all such counterparts shall together constitute one and the same Agreement. Counterparts
may be delivered via facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform
Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission
method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Effect of Headings</U>. The Section headings herein are for convenience
only and shall not affect the construction hereof. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[SIGNATURE
PAGES FOLLOW]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the foregoing is in accordance with your understanding of our agreement, please sign and return to the Company a counterpart hereof,
whereupon this instrument, along with all counterparts, will become a binding agreement between the Agent and the Company in accordance
with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Protalix BioTherapeutics, Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 50%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 5%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 5%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 40%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Dror Bashan</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dror Bashan</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">President and Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Eyal Rubin</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Eyal Rubin</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Sr. Vice President &amp; Chief Financial Officer and Treasurer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>[Signature Page to At
The Market Offering Agreement] </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 243pt; text-indent: -27pt"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 243pt; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accepted
as of the date hereof:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD COLSPAN="3">H.C. Wainwright &amp; Co., LLC &nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="3">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="3">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>By:</TD>
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">/s/ Edward D. Silvera</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 5%">&nbsp;</TD>
<TD STYLE="width: 5%">Name:</TD>
<TD STYLE="width: 40%"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Edward D. Silvera</P></TD>
<TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>Title:</TD>
<TD>Chief Operating Officer</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD COLSPAN="2">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="3">As Agent</TD>
<TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Signature
Page to At The Market Offering Agreement] </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Annex
I</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Protalix
BioTherapeutics, Inc.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
Stock</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">($0.001
par value)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TERMS
AGREEMENT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.C.
Wainwright &amp; Co., LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">430
Park Avenue</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York 10022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Protalix
BioTherapeutics, Inc., a Delaware corporation (the &#8220;<U>Company</U>&#8221;), proposes, on the basis of the representations and warranties,
and subject to the terms and conditions, stated herein and in the At The Market Offering Agreement, dated July 2, 2021 (the &#8220;<U>Sales
Agreement</U>&#8221;), between the Company and H.C. Wainwright &amp; Co., LLC (the &#8220;<U>Agent</U>&#8221;), to issue and sell to
the Agent as principal for resale (the &#8220;<U>Underwriter</U>&#8221;), and the Underwriter agrees to purchase from the Company the
shares of Common Stock specified in the Schedule A hereto (the &#8220;<U>[Initial] Securities</U>&#8221;) [, and to grant to the Underwriter
the option to purchase the additional shares of Common Stock specified in the Schedule A hereto (the &#8220;<U>Option Securities</U>,&#8221;
and together with the Initial Securities, the &#8220;<U>Securities</U>&#8221;)]*,[in each case]* on the terms specified in Schedule A
hereto. Capitalized terms but and not defined herein have the respective meanings ascribed thereto in the Sales Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[The
Company grants an option to the Underwriter to purchase up to an additional [&#9679;] Option Securities at the price per share set forth
in Schedule A hereto, less an amount per share equal to any dividends or distributions declared by the Company and payable on the Initial
Securities but not payable on the Option Securities. The option hereby granted may be exercised for 30 days after the date hereof and
may be exercised in whole or in part at any time from time to time upon notice by the Underwriter to the Company setting forth the number
of Option Securities as to which the Underwriter is then exercising the option and the time and date of payment and delivery for such
Option Securities. Any such time and date of delivery (a &#8220;<U>Date of Delivery</U>&#8221;) shall be determined by the Underwriter,
but shall not be later than seven full business days after the exercise of said option, nor in any event prior to the Settlement Date
(as defined below). If the option is exercised as to all or any portion of the Option Securities, the Underwriter will purchase that
proportion of the total number of Option Securities then being purchased which the number of Initial Securities set forth in Schedule
A hereto opposite the name of such Underwriter bears to the total number of Initial Securities, subject, in each case, to such adjustments
as H.C. Wainwright &amp; Co., LLC in its sole discretion shall make to eliminate any sales or purchases of fractional shares. For purposes
of clarity, the parties hereto agree that the officers&#8217; certificate, opinions and letter of counsel and accountants&#8217; letter
referred to in Section 3(o), (p) and (q), respectively, of the Sales Agreement are required to be delivered by or on behalf of the Company
on the Settlement Date.]*</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
of the purchase price for, and delivery of certificates for, the Initial Securities shall be made at the offices of [insert name and
address of counsel for the Underwriter], or at such other place as shall be agreed upon by the Underwriter and the Company, at 9:00 A.M.
(New York City time) on the second (or third, if the pricing occurs after 4:30 P.M. (New York City time) on any given day) business day
after the date hereof, or such other time
not later than ten business days after such date as shall be agreed upon by the Underwriter and the Company (such time and date of payment
and delivery being herein called &#8220;<U>Settlement Date</U>&#8221;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in the event that any or all of the Option Securities are purchased by the Underwriter, payment of the purchase price for,
and delivery of certificates for, such Option Securities shall be made at the above&#45;mentioned offices, or at such other place as
shall be agreed upon by the Underwriter and the Company, on each Date of Delivery as specified in the notice from the Underwriter to
the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Annex I-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
shall be made to the Company by wire transfer of immediately available funds to a bank account designated by the Company against delivery
to the Underwriter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the provisions of the Sales Agreement not related solely to the Agent, as agent of the Company, is incorporated herein by reference
in its entirety, and shall be deemed to be part of this Terms Agreement to the same extent as if each such provision had been set forth
in full herein. Each of the representations and warranties set forth in the Sales Agreement shall be deemed to have been made at and
as of the date of this Terms Agreement [and] [,] the Applicable Time [and any Date of Delivery].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the foregoing is in accordance with your understanding of our agreement, please sign and return to the Company a counterpart hereof,
whereupon this instrument, along with all counterparts, will become a binding agreement between the Underwriter and the Company in accordance
with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
TERMS AGREEMENT AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS TERMS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED
IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO ITS CHOICE OF LAW PROVISIONS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>[Signature
Page Follows]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">* &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Include
only if the Underwriter has an option to purchase additional shares of Common Stock from the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Annex I-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Protalix BioTherapeutics, Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%">&nbsp;</TD>
    <TD STYLE="width: 48%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Accepted
as of the date hereof:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD>H.C. Wainwright &amp; Co., LLC &nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 48%">By:</TD>
<TD STYLE="width: 52%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>Name:</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>Title:</TD>
<TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"></P>

<!-- Field: Page; Sequence: 30; Options: NewSection Last; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex I-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>tm2121219d1_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

                           <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 79%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2121219d1_ex5-1img01.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD>
    <TD ROWSPAN="6" STYLE="width: 21%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Mayer Brown LLP</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">1221 Avenue of the Americas<BR>
    New York, NY 10020-1001<BR>
    United States of America</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">T: +1 212 506 2500</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">F: +1 212 262 1910</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">mayerbrown.com</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-top: 12pt; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 11pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Protalix BioTherapeutics, Inc.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2 Snunit Street</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Science Park, POB 455</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Carmiel, Israel</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Re:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">P</FONT>rotalix
BioTherapeutics, Inc.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have acted as counsel to
Protalix BioTherapeutics, Inc. a Delaware corporation (the &ldquo;Company&rdquo;), in connection with the issuance and sale by the Company
from time to time of shares of its common stock, $0.001 par value (&ldquo;Common Stock&rdquo;), having an aggregate offering price of
up to $20,000,000 (the &ldquo;Shares&rdquo;), pursuant to a Registration Statement on Form S-3 (Registration Statement No. 333-230604)
(the &ldquo;Registration Statement&rdquo;), filed with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) under the
Securities Act of 1933, as amended (the &ldquo;Act&rdquo;), the prospectus, dated April 12, 2019 (the &ldquo;Base Prospectus&rdquo;),
and the prospectus supplement, dated July 2, 2021, filed with the Commission pursuant to Rule 424(b) of the Rules and Regulations of the
Act (the &ldquo;Prospectus Supplement&rdquo;). The Base Prospectus and the Prospectus Supplement are collectively referred to as the &ldquo;Prospectus.&rdquo;
The Shares are to be sold by the Company in the manner described in the Registration Statement and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with this opinion,
we have examined copies, certified or otherwise identified to our satisfaction, of: (i) the Certificate of Incorporation of the Company,
dated March 30, 2006, as amended by that Certificate of Amendment, dated August 15, 2016, that Second Certificate of Amendment, dated
January 10, 2019, and that Third Certificate of Amendment, dated December 16, 2019; (ii) the Bylaws of the Company, dated March 31, 2016;
(iii) certain resolutions of the board of directors of the Company, relating to the issuance and sale of the Shares; (iv) the Registration
Statement; and (v) the Prospectus. In addition, we have examined originals or copies, certified or otherwise identified to our satisfaction,
of certain other corporate records, documents, instruments and certificates of public officials and of the Company, and we have made such
inquiries of officers of the Company and public officials and considered such questions of law as we have deemed necessary for purposes
of rendering the opinion set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with this opinion,
we have assumed the genuineness of all signatures and the authenticity of all items submitted to us as originals and the conformity with
originals of all items submitted to us as copies. In making our examination of documents executed by parties other than the Company, we
have assumed that each other party has the power and authority to execute and deliver, and to perform and observe the provisions of, such
documents and has duly authorized, executed and delivered such documents, and that such documents constitute the legal, valid and binding
obligations of each such party. We also have assumed the integrity and completeness of the minute books of the Company presented to us
for examination. With respect to certain factual matters, we have relied upon certificates of officers of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Mayer Brown is a global services provider comprising
an association of legal practices that are separate entities including<BR>
Mayer Brown LLP (Illinois, USA), Mayer Brown International LLP (England), Mayer Brown (a Hong Kong partnership)<BR>
and Tauil &amp; Chequer Advogados (a Brazilian partnership).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5.75pt; padding-left: 1.45pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mayer Brown LLP</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5.75pt; padding-left: 1.45pt; font-size: 10pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: left; vertical-align: top; width: 48%; padding-left: 0in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2, 2021</FONT></TD>
    <TD STYLE="width: 52%; font-size: 10pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: left; vertical-align: top; padding-left: 0in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page </FONT>2</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based upon, subject to and
limited by the foregoing, we are of the opinion that the Shares have been duly and validly authorized and, when and if issued and delivered
against payment therefor in the manner contemplated by the Registration Statement and the Prospectus, will be validly issued, fully paid
and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not express any opinion
herein concerning any law other than the Delaware General Corporation Law and the federal laws of the United States of America, as in
effect on the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We hereby consent to the filing
of this opinion letter as Exhibit 5.1 to the Company&rsquo;s Current Report on Form 8-K to be filed with the Commission on or about July
2, 2021 which will be incorporated by reference in the Registration Statement, and to the reference to us under the caption &ldquo;Legal
Matters&rdquo; in the Prospectus, which is a part of the Registration Statement. In giving such consent, we do not hereby admit that we
are acting within the category of persons whose consent is required under Section 7 of the Act or the rules or regulations of the Commission
thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 55%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 45%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Mayer Brown LLP</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Mayer Brown LLP</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tm2121219d1_ex5-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2121219d1_ex5-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  A 0@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]QOVD_BT/
M@+^SUXW\:[89&\*:%>:K&DN=DCPPNZ*V.<%@!QZUSO[#G[4NG_MH?LJ^#/B/
MIZQP'Q%IZ27MLC9%E>+\EQ".^%E5P,\E=I[U\]?\'#'Q<_X55_P2\\9Q)-Y,
M_BFZL]#CPV"XDE$D@'_;.)\^V:^6/^" 'Q/\2?L8?M/>+_V8OB)BUG\06=OX
MH\/C<3$)WMDEE1"0.)8&1NG#6[CDM7TN&R95LHGBX_'&3:7>*2YONYDSYS$Y
MQ*CFT,)+X)1LWVDV^7[TFC]#O^"DG[:%K^P/^R!XH^(SP6U]J=BBVFCV4[%4
MOKZ4[8HSCG;]YVQSM1J]>^'GC6U^)/@#0_$5AS8Z_I]OJ-N<YS'-&LB\_1A7
MXT_\%X?B%XD_;_\ VR%^!O@)EN=+^#6@:AXHUYB3Y/VJ.V\Z4M@'F.+9$F?^
M6EPP[U]]?\$./C"WQF_X)@_"^ZEE,USH=B^@S$MDK]DD:*-?PB$=&.R98?*J
M6*?QR>J[1DO=_P#26_F&"SAU\TJX5?!%:/NXOWOS2^1]:5\KP_\ !371)?\
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M_M%^'8(_#_A&QTQ=.M=/GEC74+UG@M[9)9(E8D!EMVD8\@,Z+N)!-=3_ ,'
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MRDXREO[KO[R\^_S-L/@<0LKJX"LKN*E&/]Y6]U^7;RL>,_\ !!CX0Z)\*_\
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/ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>plx-20210702.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.9a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWamJabOdzZR+yYkxtmB9bTnajyAsmeDPuyEHrFHWgc0L -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:plx="http://protalix.com/20210702" elementFormDefault="qualified" targetNamespace="http://protalix.com/20210702">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://protalix.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="plx-20210702_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="plx-20210702_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>plx-20210702_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.9a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>plx-20210702_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.9a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://protalix.com/role/Cover" xlink:href="plx-20210702.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://protalix.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>tm2121219d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="plx-20210702.xsd" xlink:type="simple"/>
    <context id="From2021-07-02to2021-07-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-07-02to2021-07-02">0001006281</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-07-02to2021-07-02">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2021-07-02to2021-07-02">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2021-07-02to2021-07-02">2021-07-02</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2021-07-02to2021-07-02">Protalix BioTherapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-07-02to2021-07-02">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2021-07-02to2021-07-02">001-33357</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-07-02to2021-07-02">65-0643773</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-07-02to2021-07-02">2 University Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode contextRef="From2021-07-02to2021-07-02">07601</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressAddressLine2 contextRef="From2021-07-02to2021-07-02">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2021-07-02to2021-07-02">Hackensack</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-07-02to2021-07-02">NJ</dei:EntityAddressStateOrProvince>
    <dei:CityAreaCode contextRef="From2021-07-02to2021-07-02">201</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-07-02to2021-07-02">696-9345</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2021-07-02to2021-07-02">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2021-07-02to2021-07-02">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2021-07-02to2021-07-02">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2021-07-02to2021-07-02">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2021-07-02to2021-07-02">Common stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-07-02to2021-07-02">PLX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-07-02to2021-07-02">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-07-02to2021-07-02">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140705925181384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul.  02,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Protalix BioTherapeutics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001006281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">65-0643773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 University Plaza<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hackensack<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">696-9345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M5_#T3N%YY"OAFA%R]L"2RD3A.E.M+(O%EEP)-5]SS5*>61&:,W(KPR8">E&
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M%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.<V"3J9B+7D%=*RHC_#K3),
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MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
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M/UY_ 5!+ 0(4 Q0    ( *J(XE('04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ JHCB4BJIN@KN
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ JHCB4IE<G",0!@  G"<  !,              ( !S $  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    " "JB.)26ZR8\4H$  #2$   &
M            @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ JHCB4I^@&_"Q @  X@P   T              ( !C0P  'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    " "JB.)2EXJ[',     3 @  "P
M    @ %I#P  7W)E;',O+G)E;'-02P$"% ,4    " "JB.)2JL0B%C,!   B
M @  #P              @ %2$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ JHCB4B0>FZ*M    ^ $  !H              ( !LA$  'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ JHCB4F60>9(9 0  SP,
M !,              ( !EQ(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/  D "0 ^ @  X1,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2121219d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://protalix.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm2121219d1_8k.htm">tm2121219d1_8k.htm</File>
    <File>plx-20210702.xsd</File>
    <File>plx-20210702_lab.xml</File>
    <File>plx-20210702_pre.xml</File>
    <File>tm2121219d1_ex1-1.htm</File>
    <File>tm2121219d1_ex5-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm2121219d1_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2121219d1_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "plx-20210702_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "plx-20210702_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "plx-20210702.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "plx",
   "nsuri": "http://protalix.com/20210702",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2121219d1_8k.htm",
      "contextRef": "From2021-07-02to2021-07-02",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://protalix.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2121219d1_8k.htm",
      "contextRef": "From2021-07-02to2021-07-02",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r9",
      "r11",
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r10": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r11": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r12": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r13": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r14": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r15": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r16": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001104659-21-088982-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-21-088982-xbrl.zip
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M@I25B?E?LIN#;4MVT<?R>FTXF:1>_@%02P,$%     @ JHCB4L* #'( "P
MX8<  !0   !P;'@M,C R,3 W,#)?;&%B+GAM;,V=76_CN!6&[POT/[#>FQ88
MQW&"+9#LS"XRGF1A;#9)8\]LVT6QH"7&$2*3 24G]K\O*8FR1/)(2HJ2S$5&
M([Z'>BD^(:D/4A]_VFU2]$)XEC#Z:30].AXA0B,6)W3]:?1U,;Y8S.;S$<IR
M3&.<,DH^C2@;_?3CG_^$Q,_'OXS'Z"HA:7R.OK!H/*</[ =T@S?D'/U,*.$X
M9_P'] VG6[F'724IX6C&-L\IR8E(* ]\CKX_.L-H/!Z0[3="8\:_WL_K;!_S
M_#D[GTQ>7U^/*'O!KXP_94<1VPS+<)'C?)O5N1WOCJN?,OQCFM"G<_EKA3."
MQ.FBV?DN2SZ-Y'&KP[Z>'C&^GIP<'T\G__SU>A$]D@T>)U2>MHB,5)3,Q18W
M/3L[FQ2I2FHH=RN>JF.<3I2=.F>1FG3H&TZRY#PK[%VS".=%K?<>!H$*^;^Q
MDHWEKO'T9'PZ/=IE\4B=_.(,<I:2>_* BF*>Y_MG05*62!!&U;Y'3A[L9E+.
M)S)^0LD:YR26!SJ3!YK^71[HNVKW-5Z1=(2D4O !ENNLE5<5-'%M]H[PA,67
M]'VN]6A/]L7?#L__AP(TXYT78<ERG+[+?#/2N>T;\KXS?HAS?Z9%,T_>=Z8;
MD?\7V[EI^<VGUWY>4[GS6FRU+))=+CHP$BN3,HN.%K@X0M$Q5'G7N;.HE6\J
M6W/&S;++GK'(,R/1T9J]3&*2B+Q/CN7&6&Z,CZ=5B_V=V/7'C(GAP,4JRSF.
M<I5?49A/(TOZ1#<FE1=<N<,\ZBEBI9A$3'10S_DX+4]F&?[ V<9ZV*KLS)+X
M1[JJX\N3(PX!&&W).,G8ED?D3773= N=I<K1)A4*.:XB=/QU,?JQT*#?E>H_
M'R>'7)Q5MQ@.;3>$YDN1KZ4<[617E6TSI>JZF19$55L,Z36M)$AJO%3SA3A\
M+"U<I7AM*826[JJBK;943;<2@ZAJFR.]KFL-DB*_E?V%9!%/GN4POZLT+9GS
MJK>8- AH:,("P30&\]#0>FWJ[\DZD5V.-"*O?HG<V=&P 7K7G4&G;;UWL(J#
M0&>(0[#_: :A.LHK31>4;G%Z3YX9[X*H+7/-CLVDCDQ3$Q0I%F,@(*46E6*O
M7/QC*Z[M"4_WO6@82M=T %9U0#194(S8O8&8U/(02%ER3+-$-FF]J)A2YY<D
M@%GC\D33!44+8 Z^;*GU(?"R>"1I*A\B8-K?N-C$KIF!#>O4F,J@N 'M@>04
M$:@*"0V>RQ<Y@A>#J(%%;NA](F38[J*H%@<+DNYP($M%&))Q7GEJ/,CH(<E0
MNF8(L*K3H\F"XL;N#22FE*-"'PHJES0>!$JM\X.)9M,.224*$)&VLSY A-H_
M'E=)%N&T='0E]F4=A;1H76,"VM51,81!X0*Y Y$I Q0Y14@ V/R+8#X,FH;2
M#S*&53LPM2Q 7'1O?;!(O4=49EO.6][A/@B6.GO0VV.V?N8+Z(+ I<><\22X
ME+=P\=HG7=(\R??R=;V;[69%N*6(IL05(9 Y18:>'@01@"F=A%*&I Z50H_U
MKYXVT%R^*@D62I>YY<!NLLU"6Q,0#U9C !,';?'FJD<N9J*MXCB=TYCL?B%[
ML'2&SBT9@,TV&IHH(#;LS@ X*C$JU$C(/>)QQY,-YOM%$O5T'J;0+2"0T38A
MNBH@1 !K ".5&BWF,_]]RQ+OYK& -GE(RO?0>U@!]6Z1Z;'=)@<0!P10MT.
M(Q&$VE'^<9K3B/%GUGB=8L:VHDG<SU@,CUQZHMRB-:@(;< Z0P+";(A/ +96
MZ(?RG1?$Y"2B(@,D<_#(W44<B].55?]<)Y1,P;-@U;IEK,-NFRR+,"">8'<
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M#XT^S/\M0/GBNERKCD5/BT<L3N/M-L]DSRKLP??1.X,</Z 84 #M,45'1$
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M5E1I#4>CK"^B#'^=5=$IG%WX\Z]@0L+??IM.X?S ^T[A77@]ZW5AK+_&Z7]
M%QEV:SB0XP9G K:I@IU,ZNCJ(LU3L *BK(XF*>YWEN/?"KY4?':C25;"!9U=
MZQ4]Y2M2F>L!W[_*X!L40(&# I],X!EP>O'PP9VKZS2/SO! #0?NH$1[:3*^
M0#GBSS5]QI^E4&K "01Q =(@K[-DAB."X<#AG..=PFN9Y^G'Z!5^*4)941=Q
M5(*(JO%\XJR6XPNZ!/ D4"ICD%J3)(?+<)7!^7X/LT3Y=;+W89^^7DP/HW<I
M'.\4/E-%+'WP.3)<O@TZ5!DF29T"=AVF7.*MSFL0.W#%Y$O\%/]AL _,7Y9P
M!LK8/.H*AECA]*H,-A^D038'05O'T3Q--KR/)"5IZQ>+&=A[(YA_8YEW5W;+
MIA)<V0NZ:WB;T@EMYC2;P;_HT.(-@(.[A"N6I:PX7WP<7R3Y.6F8.>C);ITL
M?PDT$]S9BW0VA3MSGE4UJW-0;*A]Z2#!@U[B;7M_\"C:>PF#B-X4A]&C1X\.
M3AX=?7OT>!^.^R6?/GS?8CF"\P:'5TXD:6N\?7"<Q^![)'B?_=A#O8BW?3Q;
M3N1APP%+HSBB*]*<]RE8$/#]X^\?/2)EGL!X)[!&C7GCW_&SH5C!<>'GRN5,
MEA 68#E+V/@ 4V6^G*$6I4_)'1T.>AX-$L-]-WS-U46&XJ>UPI%?X"L8^B0=
MSVBG4U@WD$B7:32ZUI71_83_=PKB=S8<'%.@]OC[0Q("?CSO[!O>ZQMP1$Z\
M)+3F>,+08F*14K&0[!F?65D8$WX3K+CZP(T4A"K^&3];\6*A)JCYF?R28%?!
M_*"<:^5D5#6^2">T#]U?QR]-BO&27P$/$\,31@32<H+B# Q%OV!T@> IHS3\
M,'RB5-'.KX+#:%\%I[>LEJ!I\-NO8/[1\0DNE[L _ARZK=>#Y 8X'!3X[*NL
M2F5L,I8$+;N:7XQ[P"*^\]WO8#6BQX^.?M8+TG72HCVS\_H%>_R>@B3\_2<X
MRY<9[!X= ]28%\45&@#\,]D$YE1W'R$]/2A^BF5MEQ&U/HU_[4F"@[+F*$5=
M)\D)"7J+_'N:E55-BK9,6 R0D)D6(B5$;O#UHR^"J0[&R@B.*WRK@@4I^6[K
MQ'.0TWX@$QBST\C\RNZ588D,+UL8AT:,*/Q3QG8U+@Z>?W@6&DCGX%==@#B9
M[N^=D'/@-[QK4^ESN%_[UB[JO5,WND_#0?>%BC[K?0*9UGNAHCN\3RPQ1PD\
M"^X%;=JR$MV:P%K0$_4QJ\1VH'%DD\DJA7_SJ0/[&)7X* 4KF%\PA\,.C\.4
M(]BQ3I4;$8_KYRS4X2 P41_MC?9Q>Q[MC=54;9Z"=4+REGL*RW)CN0A#J_A)
M)6^8'H_*7CHXY#_C7KQU>X&G_%!O'OQZOL"U2J8UJM_T(VA_6@P\))-T!E>U
MO.8+:LWR.)@E>2EB2SE3"D^//P#5$LQDOL_6=S!WN6MGR-Y!Z5J1.';7^.0Q
M;=5-)#=]Q<KNP^@]'L%IEB>S[I'&37DJP^F8TZV.7]0Z?3&?/3J#N3N#- Q\
MT!AW<IY<PYGZ3 ?3WO'AX(X/IC^3L!6ZE,'Q1%'2.+Z=F]+YI"X/#:,TN&1F
MZVKU:8V,<1JQ^?+&V\!^;K^.)%O'B_!RL%:=+LL\ ]DW"9U_U*W+"G<%]6XN
MY\(=HTZ+7_0P+ K%"V<S5J^SZU4[,)O\N2S"'>!E+^D/N+FX\11+[+K[J.=+
M[\++)-X%_LU[(\?1#(%;#[YVGI37]@J)-?$V^ WMF=HI^(OV;CECPR@LOA I
MWY1B<<V7TD@2<P^MN$6E_@+7K2QR<*R>)W42_9+@BV"QX^@4Y,-UE;'B?Y?6
M999>@L2HKBN\#7LR7MAT6(H*!TM_V <)Y);YQ?-?3M^1[.$%WM]%!NYF*OK.
M_^O@('J9I;/)#]';Y#Q]"@_^<XF'$]X?'1QH*NOYJ__4P?$K#^IB 1\Y6=0Z
MB(-14=?%_(?H6_R=P$_T=S_/DO&'Z!A&616S; (#>!L^3^"3NC!O883PSH[7
MC\HT^7 P2N'*PQ@7-&8[I&\[1H3#O.DKS<)\@RO#B[$[<!U3N;=18X(5Q/K$
MA_I5DMYYSNVON0'\OSC6+W.J? +*&0K# 7[)F(OL?,<M9Q1E/RGF+JWLG>IL
M#DHJ XTX0_67<31[C9N-=H0/T,DOV%7CAZ(=A$>I9=RI@T=FQ9WKFB^]70_[
M#/Z2YFF9S(:#YUDUGA75$NRZMZ!V0'BWCF.$F9[H%29MRTB^&/T.%N1+.!71
M?V$4%\Q%:[YF%)F,.=$["8_BJ4ED:!1C.# ^C373&L'R3W1Q.$B6858,+,AL
MM*S5I+M,J[HH,6ZP8JCNP.?+^0B6PMU ]X<LSS"YY6UH3M<NX,/T2;9I;=RJ
M.$_QINUNSU]A4N[V\%T8#GHN0/L&H;B4KV=\CZ;XU2OYJG=5;'Q_DDXI^0A'
M7>)>CU8%(X:#=LCQ43,'*\Y\["+ Z"[5](#8CK)G>#JZO:[A'3W9=U&7X2 ,
MN^C-V\OP,W\NL]*%__KO>*AO8OARMN\3SF61@"J\**[<PQ.7K48\QA+<+)J8
M#)I=M'8<5Y=J;[*_]]T^#!##S70K47P@U&+3 9/ZA$'"*-./Z1P.*T%;X//X
M*OT"Y0:[/$0[D"<X$'C9."%7O=9<-$YRDE;C,EN0K)/S(*M<E/H+)X%J*_HF
M!7R(9S1%5Q1VB8P#C$T18H3"$R3N*0ADXZ$\:WC#QMM7E*0)^E8P"(4,!^!O
M)WJ>NB VH!PHG=ZY8N=W[^M^:6'S=4C0#<R);FDJYDC/=S 85Q:7WF;ET!>=
MR-P'.3';$.%7LFDV'@Y66]C\"'O\O,$Q:YD8W<&W..J*L:(9?BX+X4P3"F]9
MXX2^FV(*$"P>FE@@Y3!#45]ADF)GH_^E)]6Z(Z]11<..W_4=T:.* CK)UQGX
MPX'_ZNX@;6WPZG0V0UWJHN:M:!#*(]3X^1@]%9<';6:<\2<. F0Y*FA.FTI&
MM%(;S"'DG-VJ5BY'R=WO/5)NGDS2YJ<9(VR0<VKB^>2"LSS1QJ%QF4F"W)UE
M'U+!U^VKC._.]&,6XR:I@A4Y /Q#I>F]VRSH727M5T]X?6K$7NYN';72,6[F
M6C'[GHV7"'ED#0J[]_WCIYR["K,ZK?-)2L_@1X+$3&<6Z$8SW7!G:4W$<!><
ME>8^NT%L#KCGT6R/UZ#9'M\0S8;1B2XX6]^C^]!L=Y.[Q:.[<BLD0;G97G0?
MNH3R<@0:6'GNG+?9.GB[%-B6345L9B1JX5E]RO\25!*.6 5C%2,8[\Q_)66)
M,'.NW3B,]I)]RO'KR2[U.U*==,6?K\(\N>#I$$'6E9TF+[D'2W;JTLK/\=N-
M:(EW&PIU&[#T@QZH0WP+RU=,LC&\ 57:FN?D_CE1\)@728EACFJSQQ3[7*;C
MG_,.$YS5#:;!7^L*G-(?WJ=U+2GV%8\<#D[V+MPSHST+. @K#L+=IV>V!:I4
M3;@0A??$IO#@XJJZKP390Q 27]0R?XI8DZ+\(?JWH^,C^+^__;27[=]25,BZ
MW!WI%%?'S3(&DJT$ES8!/70L7UG-^ER!52RQK+2:IRG#:#6*QH:0PG@,2FHX
M:,.D^%D]<HIBIBM![6J02(#Q(D%$.P89V#:98QD :/CS;"3IQ+#\H&%2X*/7
M 3(/06AA G(E6%=!4'VP8P?@N4 PZ"@=%R"%_.>ZENE-@>5[BXBP&#!,V*K<
MPW+UJWE:56O&)E"=OJ%1S%7'QFLI:;(NC%M>H'N.221X:4'5EB;L:X*MHKKD
M1*P='MB2ZY:N'6@].MX[W]\[OB$D4K\5F* Z=_15QVEVV3(_:>J\%R#B8>')
MORA:.R,3_E3PUW#0@?YJ;A">.A@5/!OK+DFO3N59M")%E7I F[\J60ZBLEZ*
ML8T(.IT QB-EXQKA[N'@0UY<S=+).9C!Z&6G(&I04H2R 4<X)BFD,7A2LZ6H
M[3U.Q.Y+B6UX8FCH$R[3Q3) [Y5^[O#.7UX+;H81.WD:_499F^H'?*T8.T^C
M_\0:8?CSYX&0M4FS0DS84<<KCKK9! -U:":N4WX:G5TOX!.G93+*QD^C-W#C
M>%E V,)D3P+@F'X+_]+:Q0>+<'OH5Z-A(#XZ/GQRM]24:"VL,;\V-A=B=?JT
M1 E!NZ'NIT>1"4"25D(GIHB._,6N8J)V_BBL"]J/O2A'=,MLAH7(,.MDIH\R
M3DQ@"S;U,0R24[M=&MH;6"N4IMI]#9MU \QTL(;#0<:%D2MRYG<XZ178"/PK
MF+N8/2/>'-V5U$&RN2B]3/)JCB""":.[-7_>G^:V.TH0[)B(&19NX^'\T\YC
MB7Y=2XFC'QQ8[F=?.*%R][?R8<J:,XP*WW4-S*UC]WRHFW%4Y(7 7UX3>B1P
M>]#@,_*-/G0%H\ _X#'G0"L7D*R_KA0YRS#=1+^ZOOW]?=R\OZWP]>Y^;&O<
MJ2M$LTTQFM/Q>(F7SB)=.<;R)LT8Y-QO-^0M3]$JN< X$).!;AA^I1'IC#V9
M2$R5RPSF0I*0C"&AQ*B0Y-$RK\ME:D(P!%)QEVI*^.TR*EB7Q/0/_R#\B=A2
M\.NM[X4P+&&'D%12EA/<+<7Z(I0SQ(/R@>N<3%)3/XN@ 9 )LS1!3_80B4RZ
M0K_@QLLR[YWNT[,47^"W8S@0Y#&M]][/^[2 <%ZSRVRRA(\*,F$#'(2(OPZ$
MK1="[0$H\CFF="SGK343Z)?6)7WO=X_<#E""C2,@J_?"89IF1(\E<G6<E:"G
MD&\'TZP<6Y(R>B?W*1??VDI[,6P18OLV=!?-[?F:459>SH2\*I,%F$'[L9C0
MN"I,!C:A.]*POO';-P-/2L5N_RV\L_T%E^-3-SBZN_W5R.]F&WQV#Y6\/,3A
M8%4 O/_F=?@;<=-6Z1/2'6;.<$!B@&+-/1,-!G]C(Z@K64VOA.][F6.*0MM0
MFC5FWYKUVC"!/LDP8HF0ETDA."\VVNB'VTFT3=5+U-(N($)NJ5X>@*'TT&V^
MFQM]]V'NK:G,4$3 FV(=.!),B"D8,G5@H]%OO$2PU]ESQ75<[/NN4[<T#0%4
MJ2'R##+0*Q>"@6(B >\<)2S@!6E9I1/6!_-BDDW!X=M=PB]5$=MUWRZ__'7[
M?]^E55I>II/_[[Z.QE_S%'QA47SSDW&_" G*-K\!V?(J=T@!%KZ"S@+'\#0T
M_#WP\DZ"^N12UFR?IDDYRS WJF:E6GR.0,V!%5#TLMWFZSD)7Y@MT.E VQI,
MH!]?_30J\@3&##_^^,VKG[B*9&]%L=GQMX_W+C#B[_(673%KEV;7(I2]9_NK
M06EN21H,H?3[O>?T[4XGG9,%CF<IJ9RMZ,L#'+#;;2)7,JZL6#QZXBL-Z^0#
MZ:?QN%B*@8FJ2JAK6X"1?B?OZ EO5N:J%XQ9V=S%46JC 0G:W8T)[/3:5DVE
M2Z)MB6T)$T;D!H%X3OD8)PZR]4\X@>ELCC>%^,G=SXA8G*=:,?X6*\*OT&V"
M2U&ESXH";2V0C? ;O@3@34FD"WU*1J$@XRH9872V7;6!X7>5<@,P#8N2;%E?
M>: QCT]T.3M2@D17A)$ZOR["&YNXY4&YX!Q#N=X>W]0G_-Q?'@>?:R4&_*CX
MO4[AR/[@2OQV"2M,H9.?BZ3\3';L7_1N;X9D>?05@U8>[4 K#^K$?P%M=A-U
M=A^*[*77'T[\:XG6FR(_^.7T]&WD/A3]FB:H" PTN;/<+:0 OXG6\67@&T:&
MVTD=J@1*F_5V8!OB4DB-0#1-LG)%GMJS(?#<P+'(&FA;5U.-X7ZT*U%0\8N7
M(S RLZ0D)G=OI5>4R!K39W0J0905];_J/.H?<E',0"I6@@0%CP5T9\UO'2?5
M133%DH6;CTDIE1=465)IV7LZ>1I523;IWE,'8L7:,R&Q9]Y(C'SAL&@'?C]\
M?Z@5[,CR.D;X"T[8*V'I-X$[8Q#">-)"%OL%@PN0&I8-]XK ,Z,$N1&E(PQX
M$[Q7.I<LORQFEPJ.774Z1\L*VV0@0#<9BU%"S6*HI8UC))8_&2:C%:<YB.[=
MW(C:\'2V(HZ^N8N&\JA]C(".5VT7W>_5*^VJ58FNN?NQ#?ZEV.6 E%NA9[&;
M:XP3,^2I'=O7 HZ0(_CHX.C)873**49B$4E6F,962I!<</G*^[./96N'@QOO
M[45QE?L0[4;KWW"</7&*BL/AX'R9(=ERKM50!J'8L83-6F8["I1:,V*@6# O
M#"\=$G)70E S\KD?7]B:@,L]7P@FS],5IC(QGKUB[C )!Z92!3X1'@SWC FJ
M;AX7/4*31L0+C<0?(&PP0 +3.L>0$ >'7)<JA/@E8^<^P'D-4N66T5:>?(CE
MO8CH2^[1FXHQPQY=9$CV00A%EDNK=D62 2V/CQ<N2,9M.FRN#=DT/='11Z%H
M_!P@3\_HG,/I3QP]?T*40_\-LJ>BH,S/(C0PE:PS>YWDYTM<M5NCZ&Y^=_G*
MTEI4DCY><7G=:MM;S)>FNNG-_;_-G8W\E1T.C) 4V;6+76W55+JM_<W,_?LP
M]-\4P\&O>EY/)Q@'@8-&/ 5LS'NQ)LGZ.Q=J$=QFK(_D2T*_U;X<E:" A%3$
M8B,J$MQW#Y(8#@2&5J;^9N:%O]2)+)*0.2A9E+8SC(T<5B(2M)"(^4T^G$K-
M=>SLGRB9HC0A 3IRXDT%:Z\M'YCO-H@-W\A3[M<&FJY*6X1U\)4*Y::,"&0-
MRW*PQLO0-(,%L?74*PZ+KZG&=(HNH5H$L(:!7J7!T7E"]=.H G4E<\U9QM)S
M!\/X./3"<]"MF(.VATD(\"03Z*K V'R!81R-%:84RK.NLT,PQ31G[)1A[](,
MQX>,>EQP8RAP1M'9PK0ZIH_:];'X'_@H5IEB46):2G<M<NZ215:3!0!NXD[T
M;]54NG+T'[<H$_M+44S(497*TT#DM(O.W0$'@_(Z-+LD+7@)JSN!OZ4?X<Q3
M8J\B1]+WDH6;>PYO1=7"+S5=@F:)CV&00,<?7$=:-9R8*P@LJRJK?9]:<!:*
M*R'J2Y8@)4KT;+%G[!4LQ2Q%[Y/\5XJLI'1UV&-Q;?;@PRC3EXCCQ#][26V]
MESNW*>75J>FT";^!@3$%)F%(1W!H);?!#27-@,%WFI-CTW1C;(5PQ* >FQ@.
M]Q8)D'%7_US"%E)2B;8.H]%P7Q"=[O>P]G+=+)+44C7W5[E#_UB"S)QD8ST%
MTCP/T9CRSK'3\VHX>QU&9CTZ?2X[#OL*RN@BP^)\VE_MP,6;>JV*7K8TU U2
MBW5%<IL"?$DVPWVJ"IP=#^C:QR6:LQH.KHKEC&&4:,R<SZZ-LG==>F/OJ5+2
M.?V(>\[N%ZBAY:PFP[]M:8AS"G]4A'R7M<%PX]N;&]$=6AN$KKV=N<$,N6P_
M1,DHF^'-;0RH]X)8J\%<$\$^Q[*%YIJXPOR;W995A#,M ^D%;5_0\>D!:+.'
MK9AOJY<_IW9^;ZZC^&HH6I4P$=:/Q&A>^XM[W6ATJ!<*29:XG5Z*?>W:,)WC
M@R/JMN5#-3"6@__>U_!W5Z_G]V8$;JRV43S>W#@*;Q*.:LTCLK#A.H:TK252
ME.=)#FO7;X;T6QV1-3H"':6E*+E5?2AP^6WT<\Q#"4V2.S1$HAO9(9^8<Y#%
M:Y@!MU'VP\$=:?OH#I0]=A;\-&T?W9&RI^*M).I1%S;P<G_F)G6;\$;4LG:3
MK(0N?AJZE"ZD$4G.D4*U:<7!3R9PZ[SV)A! 1THN@UY3N:.P)L2C$W-US1)3
MA>0-<ZHV/T@P552Y6#]^"D]#FQK(=;6GLT Y01EX8,4TFU)34P..^,/!*M5!
MES;6?KIQ-"_*^APK J.%</#,LA3N=)J/E_-1B9';&-WT;(Y#X-7"JH+<L2]M
ML-RT-2N7G$K8NE><2I:$EP@^>9D5PB8@[U^@,;/0LF]M0%\B#*IJ3IPSSC0<
MNK8]K]2X#0T746LL))%0 6:_0U5]*JKJ\5>,JGJ\0U4]J!/_^6WZ[< (/V,!
M+S8C8ZJ0P9]M4Q"PF.8CO0X*P(?=O,*,+=G<1CJ[X<Z7U+'-@T-6&X]=QN&>
M&%'<'6Y4T66L:5R4(?>H&(O-;_+CVK^55"BD**=$/U115 ,]\>(Z1?LA!\>D
M!I6+#0QL&O[. W'<>=:W'*9 RL>T'&<<KP#C\A*M=#1%*D_RC<J:P0OW.KS]
MP^'@;%.3+=S^C0PQ>\36FF*'6+QS([NF.::;F2IBQS4-%B;M#RV6YHM6&RAW
ME.ST;!6=R$1R/'!1D;[2K)6<F]B138-_@5V<=(985 UWC5R!"(N6D(^*3AQV
M><EJ!WVB!!$L/#AI5&%^D=15D5Y20P3'PL^-'-W!C=TZED& V1YSBK;A:O$U
M("N<?N14:"($K_3D\^Q22TT]30=?9EIK^@N],IS7E'QJA7YQ*:P_1%8TQCQS
M[E=9Q7818O;H=66Y1A;7]%R%"K@+C@C!1KTIZT:\2$@'.RJ6[( S X6APNP>
M4KBD&ZP=>:/!X@7/"X+R#JT5O-'%/I@JE^*Q'0V(AH/CD[!3?<BHU";OU>Y(
M.*89*R<D["=^60I@3,'\1[_5D\^J^(\5Z_7F7^]?(-,Y@I7RZ/7K9\-!HQ%!
M\(GN1@<VWU0G'SBCRG%:](S!I" 12\<!6WS,*+Y",R&9S<'S8AI'KHR,V@$0
MVL!<:T.8ZU8W "\]MN"EF=?7K6]US3XFYIH+86!P-2B.VA9GB"OI0B&V3,VW
M2^M8ULQ&J^EN^VFRLQ9.TVPG:W'J8W]/X(Y=I'NKIM)I%6^'67PJ=HB8GZW*
M5;6$@S1,&/FU)C+(V?%2<]$(C[M,RU:8:'<ZMVHJW:?S2Y?"- XFGJ?G87M-
M5I[>56LITZ:AC3I5E67DF@DVD#[]GA/E383 R-CI?:=\Y9/.D60.'*KD6JM-
M)').R=UF&4&K%1,.(^,.2:'G$*]Q&1CGJVL0]BB5DFUC;&SF Y#4^&0?X*RI
MSJ4V@@QP:N?ET=7>GI9" <?QLK;WT>TR,MP;P0] QJ9K)#:\VS W"MSD4DBN
M*+>GY/A5,D^)[,:OE>R"[JO9!EXL&/ LT\Q\D)P9I<[F2.2!.Q&[55/I%+$W
MH0.Y#PD;!I[>T1EVTM3[RGSZ7%V*N5;&=>T*#:@[8$1#1E4<SF.B.!;*8!65
MKEU8?XL,7_O4]2#\+UR IBCNJ(98$2'KP+KJE)B1R2D8%B#W!$BS16-7";HK
MNUN]55/INM5?^E*?CJI4VQ[]I\;SX"O/TVFRG$F]V#.E4&OS[>J-44K1#BPX
M"0:$Q#5#AH2$!BU6(^9K='V J Z*/:E@L*@-[*@L9&@,7,\PKD"#=)5GC"YC
M4P7C8Q2K%L.%!N<B9B9VC2&IRS1/6%PXR)[C]I5"'PS6210KCOB +#'RY1/,
MDQ3+Y\"(*9>8>9X5"1DL8Q X66W?AT6+BBIQPM#]G6$*:@>0A&O'P-:L=D+\
M1O0Q%T++:O,M>-9<0F@2/F,@A>#O/=S.HURPVRH8AB+ 7:USG]G6,S(U4QK(
M/!]J<F)5>VLYBRB(.SF ".<VJ(&#G%@2NG<*]>P!?\04&L1:@N;)QA6 TQR3
M#;BD%RUG]#K%9<4@<B;G?!XHS1M'5R5OT20=([Q!'I.4HPPU! 9L$88)GS^'
M\UKF^%T8TJB87,<8H:(G%^4U_R9*)G,P'UFYH%(]AVM^;8Z;HIQB^CQM&W\$
ME B:AR&LZK)QW?MWF2ZP/T!9:8N%S&F*.@]3!S[M%SO;%V3]AQ'(YD%P.T$\
M )_I++!#PN$,VEYQ\ZY9,P>BJ9/M2_TY0KR:0&<_WE5K9?.;F!.6/7V5/6&H
MGVOK CHWV'L@^FW3L4P::U6^715]I]9R8-B95FFQ,;K&"3OM<@A^YP>_E8=Z
MB@$D4G"=^YHV'-F?32"^;[6+MA(VE.OP^^%!(3A0PMCDO;?9=ST$CEY9E)XH
M#88C&188OT;@P9N%LT]E;5/IK8)RNL#"^Y":E/61]!R#LX? "&KX$K.<8.T'
M_WR7:F3@Q27AG@V%VRB=%5?[D8=6^]-,:PW/E(@SN*%S2Y5!4HS04JBEN0S/
MX*:BY4+*G-9>Z\UUA+7L^>#V*X1&?AM6QG&]QK)6."*G&-H+57&</46+A^=8
M-2;Y.67(/F<?Z%RQ=\[GS@(18=DZTJ[%95;I0F./7-K8AF5ET6,]AM7F^T1'
M%C-5=ZCI.@2]$^YZ6(6/8CQ+4-K  ,@J\;MSR\UAO[-?MI\*/X$C00@[U_*1
M&@[H3%GD-/)%5C0Y:GP8&)AB:V%Y+&>;?&A'LDQD4X[8T/2:6RI)"+BK5R':
MDZUBYQO69,QI+Z%.YT>[U.0HO4AFTWT?B^(#2KE<_F4*]Q .4$6K-DGG"TU*
ME:F)0:*4Q!='5-[O#Z2P<V#?=1WKQI6C._CA)\,/GWS%\,,G._CA@SKQ7R B
M\\4S628D\SJ!6X@AP,6R3AWC_8Q^.^'?>N(1Q=_=Q-ZB:ANT#5S_6M>N5IY"
MC5H8=H_5(W-P*TF7L_H:H^:]3[_J 9RR!W]AOAPOBKTK;WTWY\_&B<(H0<J$
MBK4>8P/J#&&S;C@8+T3;2NX'V'NU.*01:QF*TU'Q2TW.9[<Q#.^XZFHXW;RP
MKDP&71?T[M*<2G4DAXS"@#G6Q;??@,WC4R\[13$WCJ*XQZF-J9.>P6_)X@PB
M8+:+]^I@*1?FKXJ6.A*;6T>P$C&A-=#I&4W0/7%1C[M//-O6(:YP&PX5[#/B
MX-R10_;&":^< J8-_\KG")4] #GX\$7Z.IE^?RT>Q]<DSE]\O,A&66>*V<&)
M*8C@VH+YJ]:@S LJ,[NIW^ZZUP^_F!N/)6AF\62BU?EJG@%%([2'#ZB3PDP
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M#@N#GX*/>%/AM6[X<'#*<<+C[[\[8G3<G,)[AV -,4RIW?C2-G4+A2V<CZP
M"2;#O\S2*R9T<)SF[7.%V>9F[94M(I-D>NJB91MA(#@,JB-VM%]L94VU4UV*
M.7_IVJY!6@2<5Q+2UHM!NF(=N!-!F=(RPM?!P67$4XQ$%\O2 CZG=$S3)#]8
M+A!AP<>LF)K)TMUM7M>N]7.$%_9RAF4']JKR6(69@FEU2I#]*(-S,VZ)G]!
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MHBCVG9PY?$K=VE*IH]K0I=F4\W*:9.6,RKPK/2'=E5J\!6+3MB*2E1R_YC7
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MPUI;@QX3.Q2D0R:(P(X=<)@G_$+%C.K"UAG\B1(K\)C@>H] %9Z7>%L.1%C
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M 4@KYJ]4 B.Y3)VKO(MH;-54.E3J'UNN4FVF R6T$X"9%X!9Z B"M+G@"JY
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M<HX@+>X20)17B73*I=\0)3+%'Q?J;-H/*: _]BQO_1_F)YXC!YOY5!R57%H
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MG\,AIAJ,I-%$I7^I/A&W] E+=1B=5HBRGU"-:=#YG%O7AAX8^7?&I&AR-G*
MRF<R\%[W6$)-<=&4%$X5AW_NDQ*A@!!!JC);=6#'^<59D!,;].PX=<[E<'#&
MR9G2.T&;(KC/PN("6]*6!"?+&+&^8LT-]BIA'T_[28GBO.6ZAA*8D6?]*[O9
M1/$$.].W3+7HM1..WF.Q!X"LN$F#[/,A,T3!CK,)XU )L>W*N^74(7.ZI^_\
M+,M$C1)#\"7('NT\3AM8<O;28']I"11TVT'_$/LS*;]W3<?!#@6U$/2!<Y7O
M=DU<5#9<;$=RMU:/23+:X7PW.P^?)TCP%PT(; C/^O9KAF=]NX-G/:@S_]F#
M8(MM#X)QGQMF$GD-?A9AKA%;3 23]QD' V^@3*/;QL'8'^X)A=U,UPX'W<KV
M9J9>*V=[,W>X1EI#!9@5=E=F?E=H<O!?W/9_%>4'Y0&-HU=5F<!*.F)0[KI4
M@PI&TSPAS 72FE[W=2W"-%%APH(6]3Q&3RR1A@]NR/NKZ&AOZ;TWMTA,J,_N
MO4>!\VX:7:_TWGN]-\E@4&"T:VN[/;H*7#IIR/UD;XQ$D^A@&>*K3W/V/JGP
MAL?2Y^S)VP)G3SMJ^7E;S]@WHVQ]+'9GS$8H-$L%PJS]X.!FL?_2TW FT:_(
M9M?<@:4G#F.),Q&&X<HJ:'QJ%2-5$W)C]HZ+#HAXLCY"0I>;<J1\>5HK* ])
MEO"%,OL?7 '77C4,E[A("1,3T9=[AG07H93[.C(K)KQO P91(UZP6!4OX*3'
M/08,-E(BP\%]!PRB3XH7..[$9L" U'Z7#-LD=A#=,'3 J_2Y8@?1ZM"!;4QZ
M[[&#J"]TT)\!N:?80=07.B#9\KEB!ZVU-J$#IP*:2O53@P9_>8?D8?M6?VZY
M;W4Z1L, C0H7U!(/:WOA!7?H5MU-!+WE5K$OQ1V\)BF6>=+$_%K;1@IV\F!_
M.(ORCMR36^<6@R7Y5/=DP]QBEW?"N#&QLWKS2I-/S2NMMQM]]]?U>26EB=C,
M?&P;BLX\Z;02P>7\'&FEAV\ERJFZ#[MPL_C-9[(+US$<?1Z[<!4"XO/:A7K/
MD-_HB]J%<@(-#?PN??39TT=__YK31W_?I8\>U)G_["Y.N775_6<E57Z*\Q]R
MPK1+8ERCM5"0E[;-?4L!!#0S4^EXAN6@8N23$2CY!C#JY9?2UG<,NHDZN]7&
MVD4;!]F@&P4I7)S<3VN[JS'8JJETW(]JBT( ;XK\X!F<]^5\+I&ZW]!"Y$OQ
M:NJ<C0]Y<44,D(VJR%BJN&8<Y_9$%\P,</*XNTM-5[3 $^=ATWB,>(,)1Y57
MDJ5S; M2GD2EV<QP9_J*F5ML,:=!P5#0>*$%$6TQ>B)RNDGIV?3PF3-#B-H6
M:5F1"5X0'P15T4X"QCHUD9&YNK/0B29,1>_DI$Z7%7/&&_;,"6C6:^\&\2-W
MUW^KIM)Q_>NM4X_/L7',<[C#YV3IO4LOL_2*10#6Y]Q!R \K!9SOU!7\\Y *
M1S>S>6U1QH^_L]A?$,BX6>Q/*B,N]P-VDG;'0E\;JR#Z5LA0^_-(*RYJK[I$
MWD?=IY+V*:R9*'J:H,?1=$D-*'(A(!0^%N8AC+ND-.UNY7K]5#:5U-&4Q[2Z
M4DIC)+9@8<V5(-*%T55]*/LPAQK8N/*U3DQ*_H%"5JXEK.M:QJ4*EMO.M=9U
MJ$S7LHT[*9:>$1F&)U,+V]PZ<\Z<.7K83JYNUU0ZY.IRB\RJ=VF>7E&Y1II,
MP#9*O4'523N)1Q"$9HFQXASE((6G1<QF>49$H[Y042/&*VHE]_!OMB2J-:"P
M+BKLC(%-9E ((14 PTDDUNF[:I 5,FGQ4OF+4Z;84@ T A9T!P(.)5H03>-Y
MT @C'2"3DJ\FYMD+!#\6PU&@DCM'@4(YSP3_-2FBJD AA+B, @7,&(S =#;%
M.-L-*D=C%IX=Z8S>' ;ONH@9%ID7EA&A!EW$=-6^YU![G#T%KK'IDM4QWZ92
M6;?DP\'*-8\[%ESJ;U<-4@UJ1O/QXJU:7BK6V'A]5?]K@HT,E7+,D"BC;$S7
M"\[&<7?B-6-7'O%).@8% N?=7T+I>?G]$?'KB]G1M:S>)N@_S:Z_KSX>U52#
M;<Z1ZA 'H3"ZL\+V*2V\IT8IHL= _7)#@\TU\ L;?.#:@#3+\F7:*B#EN,=P
MD'Y<D(_7+7<.X??2T[Z*F,-+=TN$4??WPFR0,I&Y+=KTUJHOM&Y;NQ*5.PV_
M55/IT/"76Z3AGX%DH9#B"Q*[2 MUC57OD;1W>D^GKT<Y8X&ZMPB,IQ T&09Y
M,H_:'>:#-A>4Y])$WJ=I925$079#(:UVC;5Z>@!SD.?H>.]\'[D/[,BP1#2I
M7,,#JYRTI==*G:'E^0VOZ,;Z"0$4*P@BB,F]J@^\6/=\/&O4E@FZ]&$<K-(*
M_=I/UUJWF!!M!<)L6KJLM^O@'2BNJ%]O#0>?37'U747NRGHEZD [F:IM'9YO
MN16$IB@-78E.%&-]_FH*O0@8 '+V;Z8;#69RC7*\^4G8J;_[F\HF^>7OON;\
M\G>[_/(#O!OW-FK'<?3X\%/BYEWVX.\_O4VN-:#]@FE[*PR,W%UKC+_,_GUA
MTS[9(M/>GX3NOIJ8=6O41Q(G(#.$\W=12V>35!/TU(600MO2%JTKYBP=X"FW
MV9E'0?R"4E^A(<S6:8H(10ZRHYE?JYGDB;Y6A0G]$[NHN;C1X<<+<'#J:I\H
M<$HP9G(T4Y7CDSZ"V19C.5N6-,8@(AL\LU*N'+1KTA8D@6 .XV(A2=X&TSF1
M=[O.6OC'M6SO;:RNT)FY&53A%"J=@_OD&"PKQ/A6Q9@Z24F2)L7*U;+(LW'0
M;JZK;5_HHQ%Z67I%J6_06BFEM0]72DG1#1,@TYV$<37+F59IWSNA>-->B77R
M,?6K <=@OO"?FBPIS0ZGGWP#UWT.S7$S-NQ!YNH*&C29+:,]\(<N><K35,8P
MR:H1.)N^VT#7I9%L%VZ]0=/CU\71F%QF54&-O/;D!7\N0=C12@D7LQD3WSO3
MAVJ67%44E1QC_P&:H:-;H[Q5I52IOI3OW'/Q[5UFX:PH@,8B0@Z&6_U$,WAJ
MT)=1<QOA<?(\.8!T/?WS&HA7YZOJV8H"!,5P0&FV:W4_RB(![^JBN IH[]!S
MR_O8!$&5?$C;K8)YI#IU%D2T D8L:N<)6ZF\:O<[\YH=XXH%+*+)T9>OWKP[
MU>%A3(6>UH15(8,3AMWGA,O*"^D:2,W$_M?Q40QJ"L_HQ\89M?)^679W<V%8
M;T]'9?HI:)>,)U5>8]9%$Y_(0;FL#XKIP0+N<%JWME\;N_C.&^&#<.AQ8W6;
MQTB6VHL1M]:]2_2$EJA[]JW6N2L4$MW<G"5DE9:7F'LEW%[7HIKV?0VGW_;6
M_-A_9?;69JVOHTDRAYM941--D2FT EX4=HQNEIYC[MBWM44Z@UF6<*!PWV@.
M/YL2_9FY(>?4[U;NS..IM7EXLD$HW)=$Z!0QTT(;+-5FX*NP8^O$54%: 78,
MUABI:A5B% ;Z2.U570"'%I.3\!O9/&U-0 !)8_*X+=M%(K9L*LX%>W('+AC1
MC$I;'1(V)%N</O_-GPCRQ"B2:(])T W;'QH"$6GX3LY?@E#99'S=?2<V!Q!*
MK(X8TAMVEC/N"''2?(0DS>6P8UPXFV1)B2_SM8XAE#>P*K3];JUPIN!."Q*Q
MD!X6:R_;N+A,\X9YU'D!13,78K!J%<]T6<K5U^W[X4$<[P=S4[?=K[8I KHZ
M*VR E\Y[]7Y:7_<*Q M+L[<5ED472S(8,4A&7,XR9;JN+]!MQ*8050B6:/;#
M7O4FJBQK)5G\K71]Y_+H%%XRBXY/P.H[.3K^?LWTNN;0\&6YW+,]]'8BT?EY
MOE_6SPEF[L*F?=UTY>X%^(1F:28W;&-+K 77;/ !:;<12D6(<<*H1+8N!&;A
MT#/2Q*,+:[XWVH]].&)U&(" 0@1@#]X9=;QR..A])W8$?(/MSHH%-S33+KYJ
M> =IL36Q&-$6?4D;UU:/\DR$CI<^X0$[^2-D)\>>9RY=-04I_X?8=JV6'GI&
MEM4Z1!D/#Q:C-[THPUN1(78CU^8;#55%X^:%!%6'+?E("+26E=#P[5C0RJYW
MNKYKPE2MU>7VVMHWA/#!4Z?8<5.P;X[KJ4V7E;^NK:BX34&)1Y=G@ 3+LNS-
M<(:KLX@#?Z97+%"OQLS%G[1]"?Y=D,8RV@FK[&068&PUQ9V4=?_1,,ZC2VB;
MLR0H-S- K4:G$5)HE!\CM\>\P88&>GHU8&H:-I"K]TV%_R/0;2*/=P[#5DVE
MPPP9;44#/.&-),GQK"N:Q ;&;_D*K6F[MIM3[N09F<S)95'2?6EP(U(P56A_
M:!0O9K,T!^<A^@7$5#7'IJ[)?/$T>C^^*.#KKU^_C;OC7@$;"+>?Z&P[!/><
M>(4DWV^YX+0D@4O-05(<1J_RZ#R[=!7[':.. _(XQRK'@(*"Y(Z^\AS<C=)T
MU*5(*LSYCV6959-,HC:^R8C0>LBG2 +4L@5*'1D2<3P3P#\.\75RU?K6<Q H
M5RAWU5R;IA/Z8C.\*U_\/<\HDD\/@)FZ"+=C:C)1R!5XW_?-%4IFE;9$%3*%
MO"JF"3$0! N=Y9?%#!%84XX8#0>RF#3Q:SUJ*/ [:$"NB4)#\$HR?.NMDB4@
MI1'&!;1>\67;#::8=<M]I7JYQK,72W FQ_R*#.:\$\N?#U'R_=>,*/E^ARCY
M6N_&_9DLXRV*G/QF;8:FY2*"^K/;+HA ^#6Y!@WR<XE$!V2L-$F>FZ/LL%M"
MVMHJ)>POF#)@Z__X^T\O&'P0G6(T.#)9>(Q[<B,O"4O* U98.NH2"1+A'T6I
M]M:SXI!,"&ZO5[6IJ5=,8SBXR3Q^;L\CNN4TM 0*IO+BHIQ1BU&9S\L4G$\T
M LAU(J?O!K3:M]ZD9V9R'+VY_>QVUL-63:5#0DZV2$*V:2N' ^:MO .YZ/BV
MJ1[BGVD%=\;[:NYG;$(W3[6;[5OL*7X%[RLOBF65/J-R;I"<K]!6RA,)QKS&
M9#-:\ZT;M[ZBH &@D7P5>6\A@"N(^$P9<E&#2861-HR;P:(KJGRB6)<&!Z@@
M1,;%'.^]TM4J3@2+.C &B2H#G8NF*\HHD#:\C&5$L\NC':X=5G]L\C9]OYK1
M0-!I7>' G1C:JJETB*%TB\20M.?UI/K/;)\\.+'P<<IYG_V*9_&\3.8;RZ>N
MI%!/X\,H;,]'R*;T8SI><C>'SF1UMPB26N<58@=OLX;EYR!^YLMY=([1+(%8
M+5 .8M:&HL*E\'8VT%?]=%;NZLZ3C_3L5K]PZA[ -2PV9$]MQ/N?B]<=!/9,
MA/$E!;'L>W@.KELXB7[?R9L"7I,E,FH(T7\KE^%B^J,B*:GK_"1#?J&B9.%#
M7X>M\=_'(C"TN5,6/@J]X? W/[M[]C[I0"542DXJF+/8XB(T.F.R0PK=C D/
MV,*C[23@5DVE0P).MXY1J-&F/)2#MW1<7>],I0BC$P^'.T/#*/PRQI%K<I&6
M$[2OO'4!4L@;1_=J7?AQF4XZ$PJ6)NQ!<P5A8.Y4&(!GN.V=#HBAC+^B.8J7
M_W2"'"-@!CZ[2/+SU$%Q5QK!'3U?GUUD*9;.J&KY354+P@;2BM& [8!R^/67
M?F_,]_EO8M>C@OEM4[75T0<'.>?Y"+GL;BZ>:7--(EF2X0 9Y6\.&VNSS77V
M(79(#B)[A!,@L'[K(",E'.'%X?45D35-R(KPW8C-K+'-MAW'!=7!<G98:/=@
M3Q,=E1([H5XG7G2BG/*XO)P@8Y08EK)A 9AQ.MM_L8$W<2/BZ,3S?5KH.\1'
M; ! ^(SX"-O99 U^XS[Q$1@*:P(D.FIE/A,^PG?;I17[!'Q$5O8B(AZ *G_8
M5LGY%OEEK]D2-A5] >GH'=G/G>4<NX.Z55/I.*@76W103QU.:SAXKER'&UG(
MW>51S?/M(P9D$K"VUO>P:>;:4E&,_AHQ"-<*WG)/%WF. TDQ;"]Z9\YLM4[?
M>N1$B5R.POOB#? ^-DR&VK.BPR(C[$1!/2WK!JS?5!4VS32DZ'!66JSZ;KJ<
M3;/93*N^S?<=/#X.ZPTLX#WV50'# 9<%@(OS_>.G#G5G88)<.=< X_>4,@6U
MG1T,)TU6$ZE)\-T!@Q!-=_ X#!+U]4'=":S^J=#_/CK\'N7(-HBN;(M$%]59
M@G9%:<4UEPUWO4RR*F7(N3>X.U,%25:2/\ X<D6?6A>!ZSCITN$5/Q=YXLOF
MAX/[8\3_HJ?@:SG:?VS1T3Y#)JI<'+Z6[E4F-ZW99%T1HI:#9J]/N@)9JIE0
M-2.IFSCY#C5=2R-N^5",NC (,T@(O):Q-EG@1M=JLH;0\Y!^SM>$(+>5G[9I
M?N7*9*68U0/Q$\042$D()_7X5Z[-;ZI-H#HKYZOH.(X>@3D61X_CZ-LX^GL<
M?1?#+L18'Q,=/X+_#W\X?D*C//Y6JW%$!PJS748K.6N'5&#V.';4A1,'<353
MO#O2ES57Z2\O"S;#))X<?<68Q).C'2;QKW\//EMA];=WQVWU^T^O8+CSW#&<
M"*'57VME'G*\X;8UN?=GWS1.C-@X05',F;48T.:HF%>&O\A9G0M,N8.[.I^A
MI6[<>4PE)%,L]J+TUY[6/1##;8;%LE/EIJ" ^).CX[W1OAN&1NTQ\O[_MW>M
M3VU;V_Z[9_P_[.FYIP,=U^61])'V=FK 2=Q+@,&DN9E,/LBV3-3(EH\D0[E_
M_5VO_9)D8\ 00_SA] 20MM9^K;WV>OQ^TUCNY1M8Y$F0[A;EOJ6_X:+;@SF!
M#(R$?83BX/W>$D28D+RI&V7R'E,?6J\AC0]!<22QF[;H5(F.PF"L>5 TB,9S
M590>+MGZKSM;SE^?T5\#39BYKJI?K:XL\=I]3SLX. \PF()I/K;\,TXR>,58
MZ0W5CX-HU! X&Q<&!^X;09XEX04A/U@H(_@AC3):UU/C+)N.*93IP<S"Y\)S
MBK/AWYP(.[V$!6$<847O5!F)9A8R72D<)0&HS2*:F1M -R3"Y!,+)( I%X5R
MX&UW:\]X!A-3E6][E#A%]FG(;%WE+A7N:-3] ;^"L%+0GD<Y7>4(E8?I2@C?
MC,- (F&WFP,U8PKJ-1+8Y#U@7#P:SPD3+H*H=VTZ0BG46*^59[<RV$B8XAB'
M%R%U/S+V$-MYMVS%#I >W'EI=HV3E:,[1.K3X#38:[RR'KR9 +T4*:\V[/GS
MQCRNLPHRGV?%7[B(MX9P:[1$JB':..9?Z)1W?=^X_!3271NZ(+QST(@%(D2H
MQLV%%CG!;#WT4BCO\QF)N)L2%. \EM(X5^U+N^O<8,*<[6? (&)DWC/V1S]*
M^],1.]&UC]&@?U^I2\PKP7EJ%+8OAP:>P!'XQ$_SE?&BW]M![M<*R[(.SL&.
M/Z=4'8;T(Z@&#"H9R!;CVX,O2T2LH?-$6"/);SD'2(>^") .'GE%)>#8$&S)
M]CAG\85)<"#$ER%(,$8AD]0 WV$/G=[ 84ZT%E32;-R35<>@UF5&2N93FGDX
MVC<DC@=:7)\E5,S$Z6.2 $ <#MJ&_W%CL G'/5CLF_9+=NB(@HH\CRYNCRZJ
M$X[A,JKI6F&L6%<J%<;--<;#Z(IK%($+]TR!MFO!5ON8O37V(@E@3#C5>KII
M,AX<E8!I,PQ>+'8LW/$EO4LDOS>]0@9$0;%4:15U_TJE85A?#$R#A%N8-$6F
M2QC<2/^R>8'%M6CZ$NAF#[J[5@VWZ<HRQ2Z<##"U\!NPWG$IT2]X<BDJ)WZQ
M_,HFW#HQ/X0_,X&R:XYWM.5EE?@K2>Z%L-CG7PRK+/ZYS]&-XX9W<X--MMCE
M7-WD;BZBW,_]LHP_AW<?RI81O: 1G0F;-[_BH]SM5:D(2]_,>E<N4BFT<BGW
M)9O1C8DW0H>%]X^'2;UYI'OY$8!6/:R'WN2$'WA.;%U[8_WVDO"UL-?>-(Q^
M>^,A;RB-+TW(S?(5=H]G,%%ST3<=7,:"?UV5W.N6;&-Q!WN]MH"'7>R.&URH
M!F'63Z.>=59:Q>[Y,6T@SZ+2%:Y@/533X_BJE/%45,:9JXTY<7&6WBX^*JJ;
MU<[]^%5OHKK))KR[0VB>ZEY$6_-P+*BRU<TT=NG"V%"55@%.RCCA0X8- 2<S
MARO$8 :)(7%H^D^7<CR?_NF[J6\)6KU]4Z%"B\"4WZ.T8,WW&:&^6$9"'ZR$
MT]>%N'$@-W/38L[V?Y3/J:9=YXPNIRN+I-5L?\UI-=OKM)JO=6]\'5!?K;Y0
M\VAKY02.VBC,Q#UYE.1.8@\:>.V :HC%/$0^ <JYY$,&BXEUVB=QNPJ-*R66
M&A^.2_F*U19NBU=TQ^0VY98I\+_6CZM%C7(^DMFT<0J<M<TD R:9JAG6M^8N
M[0#:2,,@BM% P%K21//-!N-*@>R5FD Q+X04U7U4AH-"M^QP$K//H8[P+]91
MKOTQ.II$0Q3^#981]18)DJ&3TUA?>P417H)35)99(1JT6R&%#!&G[U(RL&60
M)4#ZQ.#QF*J?"N]"$X&%.%@5<%G.A->-OS2< ]RZL1V+M5@04EQ7D2F9P_FC
M(&.Q=H<P?4P@[>;2])8CC0GM-E5K7+4B<+RI$>3%QAA(SO>:R[%URTG%%7HN
M;3TM._](W.J80<D$Q&42Y#.[XPAE5\V&)$T[9&-883TC?E#:_YL,.ML+W:]J
M0[CP+.'^CA-OX5;*A^/="VGQBIU:YL$"@49):M:N_?X&;@^I;B.O*#N_^F3+
MTB.;,(=$=F>)QZ.4)L0=.92N:B%4V+04L!^'6F'A-4)_ #5-%H&6#E)R%VNV
M DTFI5F2L#C?!2PNIF.8A\[EBD-7M<"6CKFA8^(*F#7K#89PQW9O/-U4X,:A
M)ZY7&Z&F1Q7"U6OTKM9R<(<TJAQTVKDEQQ#-;6?G88)^E;YYO##-.DDL=Y_P
M:T4PG7PD3>.!<[0X+)I&P;A.@I]T"8%)HL!<G20O#C*?-X1[G-)RFC*YUR3!
M$P/S#?3?[>5T.B9_2B$JV)@Q.>COEZP<W%#PMBDD"1#*/PX#H3P(J\][/EIB
MAV2LN%1)$G=*O;ELN#.)@K%/1" F-]4@"?E0%"E!S3O^8T;_IKF$36X\SD,X
MS>&8A$Y/XXD6B["/G%,>,S5Z]&MXI1?"7ACJY5E656O/Z)?D__II:?Q?9L\R
MR5>GH-?ZA:RN(<<!K)M-;]S(DG&P00L[)[B Q45'%+V53:ED7U2@[^UT[$J[
ME7P;5L=H0L=G2/J6=@CRBEJ"0'L,IF SI*EQ,'%R48YU727KVCOZC3HSX9Y2
MEH;9RA5"U6LBE6$MK":I[%WYEK+I?,%IR6J)GT74V"3E0S##@:=L.CBG A86
MNAPSX XQ>F*>-I6VC<-A5.&*,DYF#;(_1G >-!T]+"+[=]+/_(0V#QPBH8K,
M/#K827E%DO 2H[WAKZP>G3WHT:.^2B 6J\)R,2:=;\3!9>.FXX%^/_'\<I5Z
M>6#L4D$CQDI#@5\R5<B8\UXGQ5K"0KIF+ W FSN8,U(?9SB9Y23F^P\[OV>N
M1E5<C,X.P7L"-!8B)E'F5 SB47>!EP+,J<UIU/&,C)"Y@:RJM:MQQ;IR=O_[
M?<82K=C]+CFJN1IZP0O7LO>WL'6NC\.\"OG1J)@-]AY"PX-I7P<(:%EOFGX7
MR:\K.MX+ ^-\N+-7OV+@UEMEQ;KB;Y5;J?"J[>$L=*YGYJ5!!TO(P!\-M![P
M<,R9;@?Q2:BTB:\]Q?2GA0L*.-%Z1II)XF"H,?U-N7(B9AY5.OML@(["?5%)
M>6#C7HA.C\W$.$D)K=H,,<+>XZ Y(&)!GX)IA0\R\@TJ@^F8:MKSQ$#U)09L
M36YS56DSZ[VV8ETY<\L[?'A+\II*7#97E^0T0".M%Y)P;#,;\R,:^DZ&4A34
M>A.H$L#?A'",P)8/\L"U/GD96Z-G!+LP(51,YR$VM,R]&\&$?$]P.--&\FQ*
MMB(Y*\"5EG-#JJX7"]ER,R\6E7<J1G)AH=B_)%(5A[#BT!:/ ]_$-*\Z#YQS
MWRIEI,Z^Y*A2JFJ]]H5R50ON,+JRW#17=='$O@K-O-9:*]:5(Q^D1*B]/;04
M?\.4N2M$D[E%B8Y7X4Z9)?7:-49HE:6^2&:)QH1?IY@\GJX<)80)C#ZW\VD4
M<WQXF ;3P30F/*(H\R'YU,8U&7W;&\/-8M7\ICT1T-6>QX453>Y $U<5>3"E
M$$FX<2M8V9B(:(Z ZR6V8EUYB3%+ QU<H?L62RA=!EZ#"T8AZ:2N36G('@P$
M138;=D)*;G32KH/1:3P3*1:@9L653L#Q_NV'1D"W5;I,2L9N%7"ZNF/>;@4N
MQFT2=Q= QI@[/O5:88!<2;[DAK9982N91;CS-6<1[JRS"-=GT[*"HC\O$[OK
MU <Q;JAWEF@"-7'+\C=@UM0TO0 ;G&*H]5HKCHL@R V7J(**1.W[!2 6#TN2
MPZTSR:,+)XD%^X^0T\TCBH8?))1F3'M.D=!N2X%M1'8\]ME)*ETUB"/Z*M)!
M+)<6"I*5KN%8!4'>]V)*@3TYL7_Y8H=UHT#;9*U,.?LT]K5MVAD;AO9PZF4:
MUS3B>JPX\2*,851TR@YZ,*YHBG06&5^OFNI);*JGJ!]^6:9^<)!H[Q/7;\4-
MG-7#YEMZ*OB9CV%=@>[KY[TT?!Q?T'YA)+$>3U$[D21R)N+/Y]&%V.B[:A!<
M97[R(24P.+C!+K+OFB-S!;NRRJ6L%)6QM,]F.:M G1&DNUWQL-Q,<CQFUY@$
M);O.\=^)0SY%YZ%%8#E@8BR3 .30?S6H"(X\0B8'UK407%HY^A)F7C+-&2<V
MTJM%D9-K6-_<3%83>P1)EL/Z5BJEK"9]TP1G!E]"#TZ]AJ.3]"5\XN*MJ4#>
M[=.[6E#+V<M :29O^NV86/=(=D,U%7G,QZ5W6=IDFM/5BOPMGQ+8+AR HMRA
MK!\P_*>I/361(/S+2-)+^YCX:JPU$9G".A=AG$P8G6=\D<2D]@*#<89393NH
M)15T-E?V28)"P2<;3C=00+#FDE'4]QA#/( !BMJQ*6O7@F0)<Q(MP9-%N:F@
MT,N3!H2>TZ"J([=NAV2$68HR7<8CH2B;+D-L<*%+<U:!9N>1C.@(6F&=,\!*
MHL(QV^=DPX(HF3%*-8$)O<TMZ_4F"RYE@$.IF<E@9Z51%9V>81L3@C,.(=C*
MG'HM9@IM)U7 "7CA;SPZ)A'CPI-"DO?C*Y?!J5%^&=\]"K)!\)\*N6A4G)*A
M6%-[XZ^%&)>>8'Y9XL65$1,Q'"Z Z!_]ICQ.)!?\N+QIG]:AG@9!3LA5+$,P
MF? ?7L^9A)P9!*]$<M=03-BA+W*THRH#ESAX/'9.*L<@RM+IA!:6JT&DSG@$
M@T<;I!>,/TN U9EO!S&+TL[#(&6F\Q#NMOUPMDJI8@[)KC)8O;2(]K$ET*)A
M,*K7]OC3H-63?O0M;,=I'OZ:ZW] IY/QU8A58GL*^P;?5?@2G&2M'X[^HMV(
M?YF(WKR(9!!TIT8)Z.LDC6"JS-(8A/TXD$@T6V/UVLMP0/H;5Q*<FN^3]+.F
M$,;A6)M2*]6552X6_7 :XAX)!Q^?P$ _[34S6)4UTQ%L$,YFD^H&E^:EHF+J
M%R(=Y?O>9:0C,7X5Z\RK8<.2OP1<Y61,;.*#+T=VF43'IB" )A8?)28_I0,Z
M'#BQ0(>,W)I1;=$&N6>[NWW$@M>2%%AFB)^VA/1P<F:LNZ.<BZ?!M(\FK+OQ
MDV@/H &EF-.5GG?;,.< IAQ.\G(V8T]J_;H.WB;>6>A-JAKH&P#/3PY!'9Z9
M: D0$)49AEV/#T=9.ARQ-Y%&.78M,BIF@__'BA@\DQ/M:Z1$)(FDD=7*S@=3
M#2:SJ.69(<[&)SLKY2P6_=@S[QFGLIGHZ=P@O^.ZKOI@IGZDEWZR\#LZ.70F
MV=#"[$)V-.LU'L[U0;UB73'^UNVM.SE<?WN+25AH>7)I6BO67*_"C\G73=!0
MT['4J64.EH#6:63\ZM1]HF$L)S9:"WXPA0N#^ "&,)A1+*F!8 MG3BD27I4P
M-2Q(!TSP2*HM#CUQUDMSI;JRREYF6>D&I=3-(\2E2I$O6JPOU.OF?E.] RUX
M2<D7ZMM@-/D5SK)F0QT>[C<0]0O!2CZK%BSC*9P6^GYC_P5?W=H!9=O*J6XZ
M@2G8_Q2%0]5FU]H%;!N!KU,;J''C%WKO_?&I?]E/FK#0-QM2W0_C.B'3HQW'
MX1B.8O4J3;)LA)0P)%NW_RF)0Y#N!/7[L^<BF7'T\:T^JY(4U<CVUG-/U#^3
M3V/U&I'/M&Q_PSF:_Q&>9W$\(='66V^ENK+*GO#BUM-&8=7F0POT),7LW.@?
MM1<E9W#>!),0=DP?OM 9]V$/[JCN&&M75#<'.RF'#V/-<S_D/7G2/&[N-=6S
MY["D]P.PA<-8[>"@P.M9&H0(/^$L]8,T0?]'AB >>K$/X'?-'OWNCXD(4[T?
MWP17L('W4K2I>?/M[&POMOGJ-:,GMKS-UQJ/ W6"Z0J)#G5KP5K\ZS]&^-D>
M?E7OQ356P&VY&W>_YO2PW75ZV)-:\P]W]=B^^]4#PW11AB3NH()?1H-I/T(&
MF]-0B.\^11.^F)RYV4)]4^&8$0"70?LEMTNP*2F\UDMA2>:MQV-&Y86+"YM_
ML@5N@1M*<J*=$9Q"Q#4UF?;BJ&^C3!*X,-^T*=N:=EC#,-DR$_8#C"S&;42H
M'7"$Z93K[\'X.X?SQXDTT+4ID$GIA?DEWK'N6F5+2=NZ&@_K[?(HIXH:+(6A
M>JY!X +K,##. (,87->%.J\?Y6;8'"P]KX9&PE9O=9D,98VAP\D^HAU$099-
M1Q2K';!OSOZ2FW?6TE"O)096(KA9]MYAMEUP44H?]_/ZE)?69^*N#JUC,2 S
M@R]+ND?AR0Q6J^8ZR]ECJ#:BU%E,%"4-32:+[3YUC6_)L"3(3S8F:$/\?3&;
M;H&>P+:Q7<$)XLK,(,?QW_1#8PFL:TDV+%AO#M6U?2AS\(,]UU5QGVWT-YW\
M?EYR!>Y,R0.")1^<BUM4]9!(C".$-(5V]8L"X&"W1.!A:<JO!Q&Y+P5-)<G"
MP@)@+#^%/#?EI6<05$Q99D.7IU*DS03&D2Z$:#MA'7I[ Q="\(]LD>) NN-M
MZHPPQ$Z!R$77FM[5;C09MZY@EPC>G[/<YG8$-X[N"3<MXF>8'%I"D11'CP,+
M(Q[4X2:,X-B,-D[5A1?\GJD'_/HZ1HQC/[<[YUX,7X@%K<+*%M%8:G%])70K
M!4&K)DCF#C'6@GR*45">U_6M><6Z8@V:G;L:-*>PTL['D6LJO&UVFZH+"P./
MZE.,/W!6%:8]C<3M^B2&\<FLB%5V8?HA3:'@T2J43S_4>/L)!;8DD06.4%"
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MJ.35%[HA8"8,<"(P.U8&@KP9)^/OC8P&][G8>X,00LP;,Q=T$S<N)RX-M<<
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M>Q'PA^P'%VKJ"^F659PZ,L:K)^\^/[N>C*I1H2*(+S ;)VF(I.YB>Q:0$I4
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M1=6ZLG4ZFKO.D1MW!>Z(PJ.E#G+]I(R=0.+0F,*72U#^J)=WM^"0N4)ZKUQ
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M.?O(==9K]P!='T^G<?B]OD+.NO#O5LP8_4Z*T7:P2LY]V=5-CE^ &BLY!?2
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M9A]D!*J5L58A2[!G2.9^(JTT4S"W":9,2/0P!%&3* ^A[Y=6$SDIB[EF5SQ
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MSGNN=GK?C7[AQ_T&$/VBT'\!4$L! A0#%     @ JHCB4@0GB,A  P  C@P
M !               ( !     '!L>"TR,#(Q,#<P,BYX<V102P$"% ,4
M" "JB.)2PH ,<@ +  #AAP  %               @ %N P  <&QX+3(P,C$P
M-S R7VQA8BYX;6Q02P$"% ,4    " "JB.)2*.M3[U<'   U60  %
M        @ &@#@  <&QX+3(P,C$P-S R7W!R92YX;6Q02P$"% ,4    " "J
MB.)2.Z\V%IX8  "0@@  $@              @ $I%@  =&TR,3(Q,C$Y9#%?
M.&LN:'1M4$L! A0#%     @ JHCB4HL]&V3JGP  ).0# !4
M ( !]RX  '1M,C$R,3(Q.60Q7V5X,2TQ+FAT;5!+ 0(4 Q0    ( *J(XE(,
MW?E.I L  "\T   5              "  13/  !T;3(Q,C$R,3ED,5]E>#4M
;,2YH=&U02P4&      8 !@"( 0  Z]H

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
